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 3 Introduction 
 
1. PREFRONTAL CORTEX 
The prefrontal cortex (PFC) is the anterior part of the frontal lobe of the 
mammalian brain, located rostrally to the premotor and motor cortices (Fuster, 2008). 
It has been classically defined and delineated attending to different anatomical 
criteria such as cytoarchitectonic features (granular vs. agranular characteristics) 
(Brodmann, 1909), reciprocal connectivity with the mediodorsal nucleus of the 
thalamus (Rose and Woolsey, 1948) or with the main nuclei of origin of cholinergic 
and monoaminergic neurotransmitter systems (Uylings et al., 2003 for review). But 
the PFC as a whole shows enormous variation across species when it is defined by a 
single anatomical or functional (electrophysiology and behavior) criterion, so it is 
now generally agreed that several anatomical and functional features have to be 
taken into account when studying this region (Uylings, 2003; Seamans, 2008). 
On the bases of these criteria, three main regions of PFC can be identified in 
the rat (figure 1). The first, the medial prefrontal cortex (mPFC), is a medial frontal 
division situated rostral to the genu of the corpus callosum. The second, the 
orbitofrontal cortex (OFC), is a ventral region located in the dorsal bank of the 
rostral end of the rhinal sulcus. Finally, the third region is the lateral prefrontal 
cortex (lPFC), also called sulcal PFC or agranular insular cortex, which is located in 
the anterior part of the rhinal sulcus (Uylings et al. 2003; Fuster 2008 for review). 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the medial (A) and inferior view (B; tip of temporal lobe resected) of the rat’s 
prefrontal cortex, showing its extent and subdivisions. Abbreviations: AId, dorsal agranular insular cortex; AIv, ventral 
agranular insular cortex, cc, corpus callosum; Cg1, dorsal cingulate cortex; Cg2, ventral cingulate cortex; IL, infralimbic 
cortex; LO, lateral orbital cortex; MO, medial orbital cortex; M2, secondary motor cortex; OB, olfactory bulb; PrL, prelimbic 
cortex; VLO, ventrolateral orbital cortex; VO, ventral orbital cortex. From Uylings et al. 2003 with some modifications 
according to Paxinos and Watson, 2007. 
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2. MEDIAL PREFRONTAL CORTEX 
The medial prefrontal cortex (mPFC) will be the focus of this thesis. This 
region of the prefrontal cortex in rats can be further divided into three areas with 
distinct anatomical and functional features (figure 2): (1) the rostral portion of the 
anterior cingulate cortex (ACC), which in turn is divided into a dorsal (ACd or Cg1) 
and a ventral (ACv or Cg2) area; (2) the infralimbic cortex (IL) and, (3) the 
prelimbic cortex (PrL) (Uylings et al., 2003; Paxinos and Watson, 2007; Seamans et 
al., 2008).  
 
 
On cytoarchitectonic grounds, these regions are considered equivalent to the 
human/primate Brodmann’s areas 24, 25 and 32 respectively. However, although the 
rat PFC is not as differentiated as it is in primates, and the appearance of new 
specializations later in the evolution is likely, dorsolateral-like features (Brodmann’s 
areas 46 and 9), including both anatomical and functional ones, are also present in 
rats.  In general, it appears that the rat PrL region is involved in attentional and 
response selection functions, as well as visual working memory, whereas the more 
dorsal regions (Cg) are involved in the generation of rules associated with temporal 
ordering and motor sequencing of behavior. The IL region plays a special role in 
Figure 2. Nissl stained coronal sections of the rat brain, showing the subdivisions of the medial prefrontal cortex 
(mPFC). Please, note that sections are not equally spaced but cover the overall extent of the mPFC [from Bregma + 5.16 
mm (top left) to Bregma - 1.56 mm (bottom right), according to the atlas of Paxinos and Watson, 2007]. Abbreviations: 
Cg1, dorsal cingulate cortex; Cg2, ventral cingulate cortex; IL, infralimbic cortex; PrL, prelimbic cortex. 
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autonomic control, and especially in the modulation of fear-related behaviors (Uylings 
et al., 2003; Paxinos and Watson, 2007; Seamans et al., 2008). 
2.1. Microscopic architecture of the rodent mPFC 
The architectural order of cells and fibers in the rodent mPFC basically 
conforms to the structural plan prevailing throughout the neocortical regions in 
mammals, but lacking the internal granule cell layer (layer IV) (Gabbot et al. 1997; 
Fuster, 2008). Therefore, the rodent mPFC is organized in five layers (figure 3) that 
run parallel to the cortical surface and are numbered from the outer surface of the 
cortex (pia mater) to the white matter as follows (Kandel et al., 2000; Paxinos, 2004; 
Fuster, 2008):  
- Layer I (molecular or plexiform layer) is an acellular layer occupied by the 
dendrites of the cells located deeper in the cortex and axons that travel 
through this layer or form connections in there. 
- Layer II (external granule cell layer) is comprised mainly of small spherical 
cells called granule cells. Some small pyramidal cells are also present in this 
layer and connect with other cortical areas from the same hemisphere. 
- Layer III (external pyramidal cell layer) contains a variety of cell types, many of 
which are pyramidally shaped and connect either with the contra-lateral 
hemisphere or with other cortical areas from the same hemisphere. In cortices 
organized in five layers, layer III receives most of the projections coming from 
the thalamus. 
- Layer V (internal pyramidal cell layer) contains mainly pyramidal neurons that 
are typically larger and more densely packed than those in layer III. Many of 
these neurons have been shown to project to the basal ganglia, the thalamus, 
many nuclei of the brainstem and midbrain, and to the spinal cord (Lambe et 
al., 2000 for review). 
- Layer VI (polymorphic or multiform layer) is a fairly heterogeneous layer of 
neurons. It blends into the white matter that forms the deep limit of the cortex 
and carries axons to the thalamus and to/from other areas of the cortex 
(DeFelipe and Fariñas, 1992; Groenwegen et al., 1997). 
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Although each layer of the cerebral cortex is defined primarily by the presence 
or absence of neuronal cell bodies, each layer also contains additional elements. 
Thus, layers I-III contain the apical dendrites of neurons that have their cell bodies in 
layers V and VI, while layers V and VI contain the basal dendrites of neurons with cell 
bodies in layer II. The profile of inputs to a particular cortical neuron depends more 
on the distribution of its dendrites than on the location of its cell body (Kandel et al., 
2000). 
 
2.2. Neuronal cell types in the mPFC 
There are two major neuronal cell types in the rat mPFC: (1) pyramidal cells, 
to which pertain most of mPFC neurons, and (2) interneurons, the 16% of neurons in 
this region (Gabbott et al., 1997). 
Pyramidal cells are projection neurons located in layers II-VI of mPFC, which 
use the excitatory amino acid glutamate as their primary neurotransmitter (they 
establish asymmetric synapses). They typically have a triangular shaped soma with a 
single axon and two separate dendritic trees (apical and basal). Whereas only one 
dendrite leaves the apex of the soma and ascends vertically into more superficial 
layers (usually reaching layer I and forming an apical tuft), several dendrites emerge 
from the base of the soma and extend horizontally within the same layer (Dégenètais 
et al., 2002). Both apical and basal dendrites of mPFC pyramidal cells branch 
extensively and are studded with dendritic spines. These spines are usually 
contacted by a single glutamatergic terminal (excitatory asymmetric synapse), 
although they may also receive dual input from both a glutamatergic terminal and 
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Figure 3. Microscopic architecture of the rat medial 
prefrontal cortex (mPFC). (A) Panoramic view of the 
rat cingulated cortex stained with cresyl violet, showing 
the five layers (I, II, III, V and VI) in which this area is 
organized. Scale bar: 250 µm. (B) Schematic drawing 
representing the five layers of the rat mPFC as they can 
be observed in a Golgi staining (modified from Fuster, 
2008). Abbreviations: WM, white matter. 
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either a GABAergic, dopaminergic, serotoninergic or cholinergic terminal or even may 
not receive any input (Kubota et al., 2007; Yao et al., 2008; Miner et al., 2003; Duffy 
et al., 2009; Arellano et al., 2007). Such configurations modulate the excitatory 
transmission at the level of the spine and have important consequences for the 
efficacy of synaptic transmission (Nimchinsky et al., 2002). The axon of mPFC 
pyramidal cells emerges from the base of the soma and projects to other areas of the 
cortex or to subcortical areas (figure 4) (Lambe et al., 2000). 
Interneurons are local-circuit neurons distributed within all layers of the mPFC 
(I-VI), that are characterized by their use of the γ-aminobutyric acid (GABA) as 
primary neurotransmitter (they establish inhibitory symmetric synapses). Contrary to 
pyramidal cells, cortical interneurons are a heterogeneous population of neurons with 
diverse morphological, electrophysiological, neurochemical and synaptic 
characteristics. Thus, multiple subpopulations of interneurons can be defined 
attending to these features, individually or in combination (Ascoli et al. 2008). In the 
rat mPFC, nearly 90% of all interneurons can be classified into subpopulations 
attending to their expression of one of three calcium-binding proteins [35-40% 
express parvalbumin (PV); 20-25 % express calbindin (CB); 25-30% express 
calretinin (CR)] (figure 4) (Kubota et al. 1994; Gabbott et al., 1997). 
 
Figure 4. Schematic representation of pyramidal 
neurons and the major interneuronal subtypes in the 
rat medial prefrontal cortex (mPFC), attending their 
expression of calcium binding proteins. Abbreviations: 
CB, calbindin; CR, calretinin; PV, parvalbumin. From 
Lewis and González-Burgos, 2008, with some 
modifications. 
CR-Cajal Retzius 
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PV-expressing interneurons in the rat mPFC are fast-spiking neurons with the 
morphology of basket cells (they innervate the soma and proximal dendrites of 
pyramidal cells) or chandelier cells (they innervate the initial segment of the axon of 
pyramidal cells). CR-expressing interneurons have variable morphology and include 
bipolar, double bouquet (both of them targeting the dendrites of pyramidal cells in 
different layers of the cortex) and Cajal-Retzius cells (Gabbott et al., 1997; 
Kawaguchi and Kubota, 1997; Somogyi et al. 1998; DeFelipe, 1997). CB-expressing 
interneurons are mainly multipolar, bitufted or Martinotti cells. The double bouquet 
morphotype, which is characteristic of this subpopulation of interneurons in primates 
and humans, has not been found in rat mPFC (Ballesteros-Yañez et al., 2005). Both 
CR- and CB-expressing interneurons in the rat mPFC are non-fast-spiking cells, but 
show different pre- and postsynaptic connections, with CB-expressing axons 
extending through cortical layers and accessing pyramidal cells of layer I, while CR-
expressing axons stop short of this layer (Zaitsev et al., 2005). A subgroup of non-
fast spiking cells that contain the calcium-binding protein calretinin (CR) also express 
vasoactive intestinal peptide (VIP) and make contacts onto other interneurons much 
more frequently than onto pyramidal cells and thus are called interneuron-selective 
interneurons (figure 4) (Gonzalez-Burgos and Lewis, 2008; Ascoli et al. 2008). 
Although it has been classically considered that nearly all neocortical 
interneurons in the mature brain have aspiny dendrites (see Markram et al. 2004 for 
review), recent reports indicate that at least six different subtypes of interneurons in 
the adult mPFC form spines along their dendrites: non-fast spiking Martinotti cells, 
non-fast spiking small basket cells, non-fast spiking double bouquet cells, non-fast 
spiking large basket cells, late-spiking neurogliaform cells and fast-spiking basket 
cells (Kawaguchi et al., 2006; Kubota et al. 2011). Dendritic spine density varies 
within these subtypes. Non-fast spiking Martinotti cells have higher spine density than 
the other subtypes of interneurons, especially fast-spiking basket cells, but this 
density is clearly lower than that of cortical pyramidal neurons or excitatory spiny 
strellate cells (Kawaguchi et al., 2006). Contrary to pyramidal neurons, synaptic 
inputs to interneurons are made mainly onto the dendritic shaft, with fewer inputs 
generated on spines. The dendritic shaft is structurally stable, but spines are 
frequently coming out and disappearing (Trachtenberg et al. 2002). Synapses on the 
shaft may be made between dendrites and very nearby axons by axonal bouton 
formation (Wierenga et al. 2008). Thus synapse formation by spine protrusion is 
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considered to select specific axons among the many presynaptic axon candidates 
(Kubota et al. 2011).  
2.3. Cholinergic and monoaminergic innervation to the mPFC 
The mPFC of rats and primates plays a role in gating the inputs of the 
cholinergic and monoaminergic systems to the rest of the cerebral cortex (Ragozzino, 
2000). Thus, although the entire neocortex receives inputs from cholinergic, 
dopaminergic, noradrenergic, and serotoninergic systems, only the mPFC sends 
reciprocal connections to the basal forebrain, locus coeruleus, and the dorsal and 
median raphe (e.g. Uylings and Van Eden, 1990; Arnsten, 1997; Everitt and Robbins, 
1997). This feedback system is presumed to modulate these inputs and, 
consequently, drugs, such as antidepressants, that affect these systems have a 
significant impact upon frontal lobe functioning. The cholinergic and monoaminergic 
inputs are presumed to modulate whatever functions are ongoing in the prefrontal 
areas. In recent years, there has been an attempt to demonstrate how these inputs 
contribute to working memory and attention in particular (e.g. Sagawachi and 
Goldman-Rakic, 1994; Ragozzino, 2000). In addition, there are dynamic changes in 
monoamine release in the mPFC when there are changes in the environmental 
demands on animals, especially under conditions of stress, fear, or other affective 
stimuli (Rosenkranz and Grace, 2001; Pezze et al., 2003). Changes in 
monoaminergic neurotransmission have a particularly intense effect in the structure 
of prefrontocortical neurons and have been linked to the etiopathology of different 
psychiatric disorders and their treatments (Castren, 2005; Lewis and Gonzalez-
Burgos, 2008). The research in our laboratory has been focused during recent years 
on how monoamines affect this structural plasticity (Varea et al., 2007a; Varea et al., 
2007b; Guirado et al., 2009) and the main objective of this thesis is to particularly 
address how dopamine influences structural remodeling of the mPFC. 
2.3.1. Dopaminergic neurotransmission 
The DA-producing neurons in the mammalian brain are localized in nine cell 
groups (A8-A16), which are distributed from the mesencephalon to the olfactory bulb 
(Kandel et al., 2000; Paxinos, 2000) (figure 5). 
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The dopaminergic innervation of the rat forebrain is mainly constituted by the 
axons of neurons residing in the retrorubral area (A8), substantia nigra (SN, A9), 
ventral tegmental area (VTA, A10), arcuate nucleus of the hypothalamus (A12) and 
medial portion of the zona incerta (A13), which follow one of these pathways (figure 
5):  
 
 
- Nigrostriatal pathway: it comes from neurons located in the SN and extends to 
the dorsal striatum (caudate and putamen). It plays a key role in the motor 
planning and execution of movement, but it is also involved in non-motor 
functions, such as cognition. The breakdown of neurons in this pathway is 
associated with the motor impairments that are characteristics of Parkinson's 
disease. 
- Mesolimbic pathway: it arises from the VTA and projects to the ventral striatum, 
hippocampus, amygdala and septum. It is particularly important for motivation, 
the experience of pleasure, and reward. 
- Mesocortical pathway: it also comes from the VTA, but projects to the 
entorhinal cortex and neocortex, mostly to its prefrontal areas. This pathway is 
believed to be important for concentration and executive functions such as 
working memory. Excessive dopaminergic transmission within these two later 
pathways is associated with the disordered thought and the inappropriate 
emotional behavior characteristic of schizophrenia. 
- Tuberoinfundibular pathway: it comes from neurons in the arcuate nucleus of 
the hypothalamus and extends to the median eminence of the hypothalamus, 
where DA regulates the secretion of prolactin and growth hormone from the 
anterior pituitary. 
Figure 5. Dopaminergic neurons and pathways in the rat brain. (A) Pathways arising from A8, A9 and A10 
dopaminergic neurons. (B) A11-A16 dopaminergic neurons and their projections. Modified from Kandel et al., 2000. 
A B 
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- Incertohypothalamic pathway: it arises from the medial portion of the zona 
incerta and innervates amygdaloid and hypothalamic nuclei involved in sexual 
behavior (Dunlop, 2007; Iversen and Iversen, 2007).  
2.3.1.1. Dopamine synthesis, release and receptors in the rat mPFC 
The dopamine found in the mPFC is synthesized in the cytoplasm of neurons 
located in the VTA from the amino acid tyrosine (Tyr) by means of the enzymes 
tyrosine hydroxylase (TH) and DOPA-decarboxylase (DDC) (figure 6). Its release in 
the mPFC is modulated in association with a variety of events and behaviors. 
Appetitive events (food reward) and cognitive processing (several forms of learning 
or attention tasks) can increase DA release in the rat mPFC for tens of minutes, but 
aversive stimuli (stress, fear or pain) are particularly potent in this regard, being able 
to elevate DA levels by about 200% and for equally long lasting periods (Neve, 
2009). A dense dopaminergic innervation can be found in all regions of the rat mPFC 
(IL, PrL, Cg1 and Cg2), being higher in layers V and VI than in layers II and III (Zhang 
et al., 2010). The major targets of these DA axon terminals are pyramidal cells and 
PV-expressing interneurons, although other interneurons may also receive 
dopaminergic innervation (Neve, 2009). 
Once released from presynaptic axon terminals, DA interacts with five receptor 
subtypes, which are divided into 2 families, the D1-like receptors (comprising the D1 
and D5 subtypes) and the D2-like receptors (comprising the D2, D3 and D4 
subtypes), on the basis of amino-acid sequence homologies and pharmacological 
and functional profiles (figure 6). Each receptor subtype has a characteristic 
anatomical distribution, with D1 and D2 subtypes being present in significantly 
greater amounts than the others, and the D1 subtype being more abundant than the 
D2. D1-like receptors are located primarily on the dendritic spines and shafts of 
pyramidal neurons and on the dendrites and axon terminals of interneurons. 
Likewise, D2-like receptors are found in dendrites and spines, but they are also 
located outside the postsynaptic density at extra-synaptic and presynaptic sites 
where they act as auto-receptors to reduce DA release (Neve, 2009). 
In this thesis we will focus our attention on the dopamine D2 subtype of 
receptors (D2R), since they have been largely implicated in the pathogenesis of 
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schizophrenia and major depression, as well as in the pharmacological action of 
antidepressants and antipsychotics (Seeman, 2010; Gershon et al., 2007). 
In the rodent mPFC, D2R are expressed by restricted populations of pyramidal 
neurons and GABAergic interneurons (Zhang et al 2010; Santana et al. 2009). 
Regarding interneurons, D2R have been mainly found in PV expressing 
interneurons, but they are also present in a subpopulation of CB expressing cells (Le 
Moine and Gaspar, 1998). 
 
 
3. NEURONAL PLASTICITY 
Neuronal plasticity can be defined as the ability of neurons to react with 
adaptive changes to intrinsic or extrinsic inputs, not only during early development, 
when the nervous system establishes precise patterns of functional connections by 
cell migration, axon guidance and synaptogenesis (see Hensch, 2004; de Graaf 
Peters and Hadders-Algra, 2006 for review), but also during adulthood. Although 
there is a decline in brain plasticity across the lifespan, the adult brain retains a 
substantial capacity for experience-dependent synaptic reorganization (de 
Magalhaes and Sandberg, 2005 for review). This plasticity is considered to be the 
Figure 6. Schematic representation of dopamine synthesis, release and receptors in the medial prefrontal cortex 
(mPFC).  Dopamine (DA) is produced in dopaminergic neurons located in the VTA from the aminoacid tyrosine (Tyr), which 
is transported into the neuron by an active transport pump (Tyr-transporter). Tyr, by means of the enzyme tyrosine 
hydoroxylase (TH), is converted into DOPA, which in turn, by means of the enzyme DOPA-decarboxylase (DDC), is 
converted into DA. DA is packaged after synthesis into vesicles, to be released in the mPFC. In the postsynaptic neuron, 
DA can interact with five receptor subtypes (D1R-D5R), which are grouped into two families (DA D1-like receptors and DA 
D2-like receptors). D2-like receptors can also be located in the presynaptic terminal, where they act as auto-receptors to 
regulate DA release. DA is destroyed by the enzyme monoamine oxidase (MAO) and re-uptaked into the presynaptic 
terminal by a re-uptake pump named DA transporter (DAT). 
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basis for learning and memory (Sutton and Schuman, 2006 for review) and it is 
crucial for adaptive responses to aversive experiences and recovery from brain 
damage and disease (see Krägeloh-Mann, 2004; Fox, 2008; Sabel, 2008 for review). 
This adaptive reorganization of neuronal connectivity involves a spectrum of 
modifications: from molecular to structural plasticity (Xerri, 2008 for review). 
3.1. Neuronal molecular plasticity 
There is evidence of a complexity of molecular mechanisms and signaling 
cascades involved in the modulation of neuronal plasticity. Many of these processes 
are largely dependent on protein dynamics in synapses, such as neurotransmitter 
receptor dynamics at excitatory and inhibitory synapses or the relationship between 
the exchange of these receptors and scaffold proteins (Renner et al., 2008 for 
review).  Synaptic input onto neurons initiates membrane depolarization and calcium 
inﬂux into the cytoplasm. This calcium signaling triggers multiple biochemical 
changes and activity-dependent transcriptional programs, which are required for 
long-term changes in neuronal function (Greer and Greenberg, 2008; Cohen and 
Greenberg, 2008). Some of these molecular changes underlie the structural 
remodeling of neurites and synapses and, consequently, they should involve 
regulation of the expression of neuronal cytoskeletal proteins and proteins implicated 
in cell to cell and cell to extracellular matrix adhesion. 
The remodeling of protein filaments in the neuronal cytoskeleton is highly 
regulated by conserved signaling pathways, which are known to accompany different 
changes in the structure of synapses, axons, dendrites and spines.  In the synapse, 
the cytoskeleton is likely to control dynamic synaptic functions and might induce 
morphological changes. In fact, microtubule-associated proteins have been 
implicated in synapse assembly and disassembly (Roos et al. 2000, Eaton et al. 
2002). Different signaling pathways are also likely to regulate the actin cytoskeleton 
at the synapse (Meyer and Feldman; 2002).  Actin remodeling in the postsynaptic 
compartment can also be initiated by a number of signaling molecules, such as the 
EphB2 receptor tyrosine kinase, via the small Rho GTPases, Rac1 and Cdc42. Other 
signaling molecules associated with the Rho GTPase pathway and with actin-binding 
proteins are also important for maintaining spine integrity (see Dillon and Goda; 2005 
for review). In addition, adhesion molecules bind to a cytoplasmic network of 
scaffolding proteins, regulators of the actin cytoskeleton, and signal transduction 
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pathways that control the structural and functional organization of synapses (Yamada 
and Nelson; 2007). Moreover, cell adhesion molecules (CAMs), such as N-cadherin, 
inﬂuence synaptic structure via indirect interactions with the actin cytoskeleton (see 
Dillon and Goda; 2005 for review). The neural cell adhesion molecule (NCAM) also 
interacts with cytoskeletal proteins. The NCAM 140 and 180 isoforms, are normally 
associated with α- and β-tubulin, as well as α-actinin 1. In contrast, β-actin, 
tropomyosin, microtubule-associated protein MAP1A, and rhoA-binding kinase-α 
preferentially bind to NCAM 180 (Büttner et al., 2003).  
Neural cell adhesion molecules can also activate “per se” transmembrane-
signalling reactions and thereby contribute to the initiation of cellular responses 
directed to the regulation of synaptogenesis and synaptic plasticity. L1 and NCAM, 
activate intracellular signaling pathways in the growth cone, mediated by two different 
members of the src family of nonreceptor protein tyrosine kinases (PTKs), pp60 (c-
src) and p59 (fyn5,6), and this activation induces neurite outgrowth (see Maness et 
al., 1996 for review). NCAM is also known to stimulate neurite outgrowth by the 
activation of both the Ras-MAP kinase pathway and the FGF receptor-PLCg-PKC 
pathway (Kolkova et al., 2000). NCAM also has marked inﬂuence on both the 
structure of spines and their post synaptic densities (Stewart et al., 2008). 
3.2. Neuronal structural plasticity 
The term neuronal structural plasticity refers to all types of changes, which 
modify the shape and structure of the central nervous system (CNS). These 
morphological changes can be organized in different levels: (a) Synaptic plasticity 
(synaptogenesis and synaptic removal); (b) Neurite remodeling (axonal and 
dendritic outgrowth/retraction) and spine remodeling; (c) Neuron-glia plasticity; 
(d) Neurogenesis (proliferation of neuronal precursors, neuronal migration and 
incorporation to functional neuronal circuits) (Xerri, 2008, for review). 
The next paragraphs will deepen into the first two levels, focusing on the current 
information available on structural plasticity in the adult brain. 
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3.2.1. Synaptic plasticity 
Synaptic plasticity is a term that describes changes in the efficacy of synaptic 
transmission, including also the structural reorganization of synapses.  
Changes in synapse number and morphology are frequently associated with 
learning. Raising animals in an enriched environment or training them on a motor 
skill-learning task   results in increases in the number of synapses in the visual cortex 
and in various hippocampal areas, including the dentate gyrus and CA3 (see 
Markham and Greenough; 2004 and Bruel-Jungerman et al., 2007 for review). 
Stereological electron microscopy studies of the hippocampal dentate gyrus have 
shown that training rats to find a hidden platform in a Morris water maze induces a 
significant but transient increase in axo-spinous synapse density and in the ratio of 
synapse per neuron (Eyre et al., 2003). 
There is also strong evidence pointing at different hormones as major players in 
synaptic remodeling. Chronic stress and glucocorticoids strongly influence synaptic 
plasticity (McEwen; 2005).  Other steroid hormones, such as the estrogens, also 
influence synaptic plasticity by increasing the density of axospinous synapses in the 
hippocampal stratum radiatum of CA1, both after estradiol treatment and during 
proestrus, when estradiol levels are naturally increased (Woolley and McEwen; 
1992). 
Aging also has a notorious influence in synaptic plasticity, especially in the 
hippocampus, where a decrease in the number of synaptic contacts in the mid-
molecular layer of dentate gyrus has been found in aged animals (see Rosenzweig 
and Barnes; 2003 for review). Similarly, the numerical density of excitatory and 
inhibitory synapses is reduced in the neuropil of the primate prefrontal cortex during 
aging (Peters et al., 2008). 
3.2.2. Axonal, dendritic and spine remodeling 
Plasticity associated with cognitive functions, with aversive experiences or with 
brain repair involves dynamic remodeling of dendritic and axonal arbors, including 
branch formation/elimination, as well as collateral branching and spine remodeling 
(Wong et al., 2000; Diana et al., 2007; Cline and Haas, 2008; William et al., 2008 for 
review). As it occurs with synaptic plasticity, neurite remodeling is also influenced by 
environmental enrichment: animals raised in this condition have an increase in 
dendritic branching in the visual cortex (see Markham and Greenough; 2004 for 
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review). Different learning paradigms also influence neurite remodeling: Passive 
avoidance response increases spine number in the mid-molecular layer of the dorsal 
dentate gyrus at different post-training times (O'Connell and Regan, 1998; O’Malley 
et al., 1998) and trace eye blink conditioning, an associative learning task, also 
increases the density of dendritic spines on the pyramidal cells in hippocampal CA1 
region (Leuner et al., 2003). Fear conditioning, another learning paradigm, increases 
dendritic spine density in the lateral amygdala (Radley et al., 2006). Moreover, there 
is a strong correlation between long-term potentiation (LTP) and morphological 
changes in dendritic spines. Several studies have shown the possible association 
between this structural remodeling with LTP (see Muller et al., 2000 a; Yuste and 
Bonhoeffer, 2001 for review).  
Abundant experiments have demonstrated that chronic stress affects dendritic 
branching: it induces dendritic atrophy in various hippocampal regions, like retraction 
and simplification of dendrites of pyramidal neurons in the CA3 region (see McEwen; 
1999 and 2000 for review). Dendritic atrophy was also observed in dentate granule 
and CA1 pyramidal neurons (Sousa et al., 2000). Chronic stress also causes 
retraction of the thorny excrescences (giant spines) upon which the mossy ﬁber 
terminals form their synapses (Stewart et al., 2005). Dendritic spines also show 
remodeling after chronic stress: for instance in the apical dendrites of CA3 neurons, 
which show increased spine density (Sunanda et al., 1995). This stress-induced 
neurite remodeling is not restricted to the hippocampus; chronic stress also induces 
dendritic atrophy in the mPFC (Radley et al., 2004; Cook and Wellman, 2004). 
Moreover, this aversive experience also induces a reduction in spine density on 
proximal basal dendrites of prefrontocortical pyramidal neurons (Perez-Cruz et al., 
2009). On the contrary, chronic stress promotes dendritic growth and spinogenesis in 
some regions of the amygdala (Vyas et al., 2002; Mitra et al., 2005).  
Antidepressants also influence neurite remodeling. For instance, chronic 
treatment with fluoxetine, an antidepressant of the selective serotonin reuptake 
inhibitor class, increases the density of spine synapses in pyramidal neurons of 
hippocampal CA1 and CA3 regions (Hajszan et al, 2005). In the same way, chronic 
administration of imipramine, a tricyclic antidepressant of the dibenzazepine group, 
also increases the density of asymmetric spine synapses in the hippocampal CA1 
region (Chen et al., 2008). 
Interestingly, the effects of chronic stress on neurite structure can be reverted 
or blocked by antidepressant treatment. Daily treatment with tianeptine, an atypical 
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antidepressant (a selective serotonin reuptake enhancer), prior to stress sessions, 
prevented the structural effects of chronic stress in hippocampal CA3 pyramidal 
dendrites (Watanabe et al., 1992). Treatment with this antidepressant also prevented 
the dendritic hypertrophy induced by chronic immobilization stress in certain 
amygdaloid nuclei (McEwen and Chattarji, 2004).  
The effects of stress on structural plasticity seem to be mediated by the action 
of glucocorticoids and excitatory aminoacids. In fact, chronic corticosterone treatment 
also results in dendritic atrophy of CA3 pyramidal cells (see McEwen; 1999a and 
2008 for review) and a recent report has also shown decreased branching, reduction 
in total dendritic length and diminished number of spines in CA1 pyramidal neurons 
(Morales-Medina et al., 2009). Significant redistribution of apical dendrites (Wellman; 
2001) and spine density (Seib and Wellman; 2003) is also observed in the mPFC of 
animals chronically treated with corticosterone. Neurite remodeling is also induced by 
corticosteroids in the amygdala (Mitra and Sapolsky, 2007; Morales-Medina et al., 
2009).  
Estrogens play also an important role in dendritic and spine remodeling within 
the CNS.  Ovariectomy decreases the density of dendritic spines in the CA1 region of 
the hippocampus, but not in CA3, and this effect can be reversed by estradiol 
replacement (Wallace et al., 2006). Furthermore, an increment of spine and synapse 
density occurs within the natural late proestrous (Moult and Harvey, 2008), when 
estrogen levels are high. In the rodent mPFC, ovariectomy decreases spine densities 
in pyramidal neurons (Wallace et al., 2006). Long-term cyclic treatment with estradiol 
in ovariectomized rhesus monkeys, does not affect total dendritic length and 
branching in the PFC, but increases apical and basal dendritic spine density (Hao et 
al., 2006).  The structure of amygdaloid neurons is also a target for sexual steroids: 
In the posterodorsal medial amygdala, dendritic spine density increases following 
estradiol injections and this effect is potentiated by progesterone (de Castilhos et al., 
2008).   
Age also influences dendritic and spine structure. Aging induces a reduction in 
spine density and dendritic tree extension in both sexes, in the mPFC and 
hippocampal CA1 of rodents. However, signiﬁcant decreases in spine density have 
been found only in the aged mPFC (Markham and Juraska; 2002, Markham et al., 
2002; Markham et al., 2005). By contrast, although aged rodents display significantly 
more dendritic material in basolateral amygdala, aging does not appear to inﬂuence 
spine density in this region (Rubinow et al., 2009). 
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4. CELL ADHESION MOLECULES 
Neuronal structural plasticity is largely dependent on cell adhesion molecules 
(CAMs). CAMs are proteins located on the cell surface, which are involved in 
stabilizing and modulating cellular interactions with other cells or with the extracellular 
matrix. They are critical for the assembly of CNS architecture during developmental 
stages and are critical for the proper function of the mature nervous system. There 
are four important families of adhesion proteins according to their functional and 
structural resemblance. These families of CAMs are: (a) The immunoglobulin 
superfamily, which includes the neural cell adhesion molecule (NCAM) and L1; (b) 
Integrins; (c) Cadherins; and (d) Selectins (see Walsh and Doherty, 1997; Murase 
and Schuman, 1999; and Chothia and Jones, 1997, for review). 
4.1. Neural cell adhesion molecule (NCAM) 
Among CAMs, NCAM is the most studied protein regarding cellular recognition 
processes and it is expressed on the surface of most neurons (Hoffman et al., 1982; 
Friedlander et al., 1986). NCAM is a surface glycoprotein (see Gascon et al., 2007; 
Maness and Schachner; 2007 and Katidou et al., 2008 for review), which presents 
three major isoforms, generated by alternative splicing, denominated NCAM 180, 
NCAM 140 and NCAM 120, based on their molecular weights (Gegelashvili et al., 
1993; Olsen et al., 1993; Kramer et al., 1997).  All three isoforms share identical 
extracellular structures, consisting on five immunoglobulin-like domains and two 
fibronectin-type III repeats. The extracellular domain is a globular structure composed 
by around 70-110 amino acids. Both NCAM 140 and NCAM 180 isoforms contain a 
transmembrane and an intracellular domain, but the NCAM 120 isoform lacks those 
domains and it is anchored to the cell membrane via a glycosylphosphatidylinositol 
(GPI) linkage. Consequently, only NCAM 140 and NCAM 180 isoforms are 
detectable in synaptosomal membranes (Persohn et al., 1989; Rougon et al., 1990) 
(figure 7). 
NCAM180 has a long cytoplasmic domain (figure 7), it is predominantly 
expressed on mature neurons and it is particularly enriched at sites of cell contact 
and postsynaptic densities (Barthels et al., 1988; Persohn et al., 1989); NCAM140 
has a shorter cytoplasmic domain (figure 7) and it is particularly expressed on 
developing neurons, mediating growth cone guidance and neurite outgrowth 
responses, although it can also be found in mature neurons, both  in pre- and 
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postsynaptic densities (Persohn et al., 1989; Doherty et al., 1992).  While NCAM140 
is expressed both by neurons and glia (Williams et al; 1985), NCAM120 is 
predominantly expressed by glial cells (Bhat and Silberberg, 1986; Walmod et al., 
2004). NCAM molecules interact with like molecules (homophilic interaction) and 
non-like molecules (heterophilic interaction) on neighboring cells or on the 
extracellular matrix to regulate their position and dynamic interactions with other cells 
by diverse signal transduction pathways (see Walmod et al., 2004 for review). The 
functional properties of NCAM are strongly inﬂuenced by the addition of long chains 
of a complex sugar, the polysialic acid (PSA) (figure 7, figure 8) (Rutishauser et al., 
1996; Bonfanti, 2006; and Gascon et al., 2007, for review). 
 
 
 
Figure 7. Scheme of the NCAM isoforms and the polysialylated form of the NCAM molecule (PSA-NCAM). The three 
major isoforms of the NCAM molecule (NCAM 120, NCAM 140 and NCAM 180) have identical extra-cellular structures (five 
immunoglobulin(Ig)-like domains and two fibronectine type III repeats), but differ in their molecular weight (120, 140 and 180 
kDa, respectively) and the way in which they are anchored to the cell membrane. Whereas the NCAM 140 and the NCAM 
180 isoforms contain a transmembrane and an intracellular domain, the NCAM 120 isoform lacks those domains and it is 
anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage. All isoforms can be modified by the addition 
of polysialic acid (PSA) on two N-glycosylation sites located in the fifth Ig-like domain. PSA is negatively charged and 
attracts H2O molecules. PSA can be removed from mammals’ brain by a phage enzyme, the Endo-N-acetylneuraminidase 
(Endo-N), that specifically cleaves α-2,8-linked N-acetylneuraminic acid polymers with a minimum chain length of 8 (see 
materials and methods, section 2.5, for more information). 
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4.2. The polysialylated form of the NCAM molecule (PSA-NCAM) 
The NCAM protein core is submitted to several post-translational 
modifications, such as phosphorylations, addition of the carbohydrate epitopes L2 or 
HNK-1, sulfation, glypiation and glycosylation (see Rougon et al., 1990; Walmod et 
al., 2004 for review). 
One of the most important glycosilation events is the addition of PSA. This 
unique and highly regulated post-translational modiﬁcation of NCAM is critical during 
brain development, neural regeneration and plastic processes, including learning and 
memory (see Bork et al., 2007 and Hildebrandt et al., 2007 for review). In mammals, 
this molecule is a linear homopolymer of α-2,8-linked N-acetylneuraminic acid, which 
chains can extend to lengths ranging from 50 to 150 units (Kiss and Rougon, 1997; 
Livingston et al., 1988). PSA is attached exclusively to NCAM at the fifth 
immunoglobulin-like domain (figure 7) (Hoffman et al., 1982; Acheson et al., 1991). 
The degree of NCAM polysialylation is tightly regulated: PSA-NCAM levels are high 
during brain development but there is a progressive reduction until adulthood (see 
Rutishauser et al., 1996; Bonfanti; 2006 and Gascon et al., 2007a for review). 
The synthesis of PSA in the Golgi compartment is catalyzed by two resident 
polysialyltransferases, ST8SiaII (also known as STX) and ST8SiaIV (also known as 
PST). Both enzymes are strongly expressed during prenatal development and this 
expression is dramatically downregulated after the perinatal period. During adulthood 
the expression of ST8SiaII and ST8SiaIV is low, but the later is more abundant than 
the former (Nakayama et al., 1996; Kojima et al., 1996; Hildebrandt et al., 1998 and 
2008). PSA has been found also on other proteins: the α-subunit of the rat brain 
voltage-sensitive sodium channel (Zuber et al., 1992), SynCAM (Galuska et al., 
2010), podocalyxin (Vitureira et al., 2010) and the polysialyltransferases St8SiaII and 
St8SiaIV, which are autopolysialylated in vivo (Close and Colley; 1998). However, 
NCAM is the principal carrier of PSA in the nervous system, where it has a 
fundamental role (see Rutishauser 1996 and 2008 for review).   
Carboxyl groups give their peculiar biochemical characteristics and negative 
charge to PSA, attracting water and ionic molecules. This large hydrated volume 
inhibits cell-cell apposition (steric impediment), which prevents both the homotypic 
and the heterotypic binding of NCAM (figure 8) (Yang et al., 1992). Therefore, the 
post-translational addition of PSA on NCAM increases the range and magnitude of 
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intermembrane repulsion by increasing the nonspecific repulsive force between cells 
(Johnson et al., 2005). These anti-adhesive properties of PSA-NCAM are 
particularly evident during neuronal migration. This molecule is expressed by neural 
precursors migrating from the subventicular zone (SVZ) to the olfactory bulb by a 
mechanism in which the cells move forward in a stream by using each other as a 
substrate and PSA-NCAM enhances the cycles of adhesion and de-adhesion 
(Rousselot et al., 1995; Petridis et al., 2004). PSA-NCAM expression also 
participates in the axophilic migration of luteinizing hormone releasing neurons to the 
forebrain (Yoshida et al., 1999). Moreover, PSA-NCAM plays a permissive role in 
axon guidance, reducing the fasciculative interactions between axons and allowing 
them to respond more effectively to a variety of extrinsic signals and to reach their 
target, both in the peripheral and in the central nervous systems (see Rutishauser 
and Landmesser, 1996; Kiss and Rougon, 1997 ; Brusés and Rutishauser; 2001; 
Rutishauser 2008 for review). 
 
 
Multiple lines of evidence implicate NCAM in synaptic functions and suggest a 
role of PSA-NCAM in synaptic strength modulation (see Dalva et al. 2007; 
Dityatev et al. 2008, for review). There are several mechanisms by which PSA-NCAM 
might regulate synaptic strength. One possibility is suggested by the finding that 
Figure 8. Illustration showing the anti-adhesive proprieties of the PSA-NCAM molecule. NCAM can be post-
translationally modified by the addition of polysialic acid (PSA). PSA is negatively charged and rapidly becomes hydrated 
(right) (see also figure 7), preventing both the homotypic and heterotypic binding of NCAM by a steric impediment and, 
therefore, increasing the non-specific repulsive force between cells. Abbreviations: CAM, cell adhesion molecule, NCAM, 
neural cell adheshion molecule, PSA-NCAM, polysialylated for of the NCAM. 
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neuronal activity increases the expression PSA-NCAM on the cell surface (Muller et 
al. 1996; Kiss et al. 1994; Schuster et al. 1998), and enzymatic removal of PSA (by 
Endo-N, see figure 7) or its blockade with antibodies, prevents LTP, LTP-associated 
formation of perforated synapses and LTD in the CA1 region of the hippocampus 
(Becker et al., 1996; Muller et al., 1996; Dityatev et al., 2004). Hippocampus-
dependent spatial learning protocols increase the expression levels of PSA-NCAM 
(Venero et al. 2006) and mice deficient in one of the two polysialyltransferases 
St8SiaII or St8SiaIV show normal basal synaptic transmission but defects in LTP and 
LTD in CA1 (Eckhardt et al., 2000; Angata et al., 2004). Functionally, PSA weakens 
homophilic NCAM interactions (Rutishauser 1996 and 2008), indicating that PSA–
NCAM might mediate a downregulation of adhesion that is a prerequisite for 
structural changes that underlie plasticity. In this model, PSA linkage acts as a switch 
between structural stability and plasticity; however, this model has not been verified. 
PSA–NCAM might also indirectly regulate synaptic plasticity through interactions with 
other synaptic proteins. Currently, NCAM and PSA–NCAM have been shown to 
interact with a large number of molecules or signalling pathways that regulate 
aspects of LTP including AMPARs (Vaithianathan et al. 2004), NMDARs (Hoffman et 
al. 1998), brain-derived neurotrophic factor (BDNF)–tyrosine receptor kinase B (TrkB) 
signaling (Muller et al. 2000), the spectrin-based scaffold (Wechsler and Teichberg, 
1998; Sytnyk et al., 2002; Sytnyk et al., 2006), the fibroblast growth factor (FGF) 
receptor (Cambon et al. 2004) and the non-receptor tyrosine kinase Fyn (Beggs et al. 
1997). Unfortunately, in most of these cases, a direct link between the interactions 
and LTP has not been demonstrated. The exception is BDNF–TrkB signalling, where 
defects in LTP caused by enzymatic PSA removal are rescued by exogenous 
treatment with BDNF, indicating that PSA-dependent defects in LTP are due to 
decreased BDNF signaling (Muller et al. 2000). Nevertheless, the numerous 
interactions between NCAM and LTP-influencing pathways show that NCAM is a 
multifunctional protein capable of influencing synaptic plasticity at multiple levels 
(Dalva et al. 2007). 
PSA expression is also important in the development and function of the 
immune system. For instance, human NK cells modulate NCAM expression and its 
degree of polysialylation according to their activation state (Drake et al., 2008; Drake 
et al; 2009).  
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PSA and NCAM have also a prominent role in oncology. These two 
molecules have been found in different human cancers, including small-cell lung 
carcinomas and multiple myeloma (Miyahara et al., 2001; Suzuki et al., 2005). 
5. PSA-NCAM, ST8SiaII AND ST8SiaIV EXPRESSION IN THE ADULT mPFC 
As we have commented before, although PSA-NCAM levels are very high during 
the embryonic and early postnatal development of the mammalian brain, the 
expression of this molecule during adulthood is restricted to brain regions that display 
a high degree of neuronal plasticity, including the mPFC (Bonfanti, 2006; Varea et al. 
2005; Varea et al. 2007c; Varea et al. 2009). 
In the frontal cortex of rodents, PSA-NCAM begins to be highly expressed at 
embryonic day 14 (E14) and its level of expression remains very high from this 
moment until postnatal day 5 (P5), when it starts rapidly to decrease. At P21, PSA-
NCAM expression in the mPFC reaches similar levels to those found during 
adulthood and they continue stable until old age (Seki and Arai, 1991; Probstmeier et 
al. 1994; Kurosawa et al. 1997; Oltmann-Norden et al. 2008; Varea et al. 2005; 
Varea et al., 2009). 
PSA-NCAM expression has been described in neurons and neuropil elements in 
the adult mPFC of both rodents (Varea et al. 2005; Gómez-Climent et al. 2010) and 
humans (Varea et al. 2007c). PSA-NCAM expressing cells in the rodent mPFC 
mainly show a multipolar morphology and they are found in all regions (IL, PrL, Cg1 
and Cg2) and layers (I-VI) within the mPFC, although their density in deep layers (V-
VI) is higher than in layers I-III (Varea et al. 2005; Gómez-Climent et al. 2010). 
The changes observed in PSA-NCAM expression during mPFC development are 
in accordance with changes in the mRNA levels of both ST8SiaII and ST8SiaIV 
polysialyltransferases. The expression of ST8SiaII in the mPFC is very high from E14 
to P5, when it dramatically begins to decrease until P14, when its level is similar to 
that in the adult cortex. By contrast, the decrease in ST8SiaIV expression from P5 
onwards is very low and, although ST8SiaII mRNA levels are two-fold higher than 
those of the ST8SiaIV during embryonic and early postnatal development, ST8SiaIV 
is the major polysialyltransferase of the adult brain (Kurosawa et al. 1997; Angata et 
al. 1997; Hildebrandt et al. 1998; Ong et al. 1998; Galuska et al. 2006; Oltmann-
Norden et al. 2008). Analysis of single polysialyltransferase knockout mice has 
revealed that ST8SiaIV is solely responsible for PSA-NCAM expression in mature 
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interneurons and in most regions of cortical neuropil. By contrast, ST8SiaII is the 
major polysialyltransferase in immature neurons of the paleocortex layer II and the 
hippocampal subgranular zone (Nacher et al., 2010). 
5.1. Neurochemical phenotype of PSA-NCAM expressing cells in the adult 
mPFC 
PSA-NCAM expression in the rodent mPFC can only be found in mature neurons 
that are not recently generated. No astrocytes, oligodendrocytes, microglial cells or 
pyramidal neurons are found to express this molecule. Most PSA-NCAM expressing 
neurons are interneurons and belong to different subpopulations, attending their co-
expression of calcium binding proteins (CB, CR and PV) or neuropeptides 
(cholecystokinin, CCK; vasointestinal neuropeptide, VIP; neuropeptide-Y, NPY; and 
somatostatin, SST). Regarding the expression of calcium-binding proteins, PSA-
NCAM immunoreactive neurons in the mPFC mainly co-expressed CB and rarely CR 
or PV. PSA-NCAM/CB double immunoreactive cells were most frequently found in 
deep layers (V-VI), although they could also be observed in layers II and III. The 
highest percentage of co-localization of PSA-NCAM expressing cells with 
neuropeptides was found when studying SST. These double-labeled neurons were 
mainly located in deep layers of both prelimbic and cingulate cortices. The co-
localization with NPY, CCK and VIP was lower than that of SST. PSA-NCAM/NPY 
double labeled neurons were located most frequently in deep layers, especially in the 
cingulated cortex (Varea et al. 2005; Gómez-Climent et al. 2010). The phenotype of 
PSA-NCAM expressing neurons in the mPFC of adult humans (Varea et al., 2007c), 
mice (Gómez-Climent et al. 2010) and cats (Varea et al., unpublished results) is very 
similar to the phenotype described for these neurons in the mPFC of adult rats 
(Varea et al. 2005; Gómez-Climent et al. 2010). 
6. PSYCHIATRIC AND NEUROLOGICAL DISEASES 
Impairments of dopaminergic neurotransmission affecting mPFC function are 
implicated in the pathogenesis of several psychiatric disorders such as schizophrenia 
and major depression (Waxman, 2005). In Parkinson’s disease, the dopaminergic 
system is severely affected; not only there is a massive death of dopaminergic 
neurons in the SN (responsible of motor symtoms), but also in the VTA, which has 
been related to the cognitive deficits and depressive symtoms frequently found in 
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these patients (Dubois and Pillon 1997; Zesiewicz and Hauser 2002). Decreased 
levels of D2R have been found in the mPFC of both human and animal models of 
schizophrenia (Knable et al. 2001; Zhang et al. 2010), major depression (Knable et 
al. 2001) and Parkinson’s disease (Kaasinen et al. 2003).  
During recent years, increasing evidences indicate that, in addition to 
neurochemical alterations, changes in the structure and connectivity of neurons in the 
mPFC may also underlie the pathogenesis of these diseases and that 
pharmacological treatments may revert these changes by enhancing the plasticity of 
neuronal connections (Sairanen et al. 2007; Varea et al., 2007a; Lewis and 
Gonzalez-Burgos, 2008; Solis et al., 2007). This findings support the “neuroplastic 
hypothesis of depression” and extent it to other psychiatric and neurological 
diseases (Duman, 2002; Castren, 2004; Castren, 2005) (figure 9). 
 
 
 Although most of the studies on neuronal structural plasticity have been 
focused on principal neurons (figure 9), there is abundant evidence that, in these 
psychiatric and neurological disorders, interneurons and cortical inhibitory networks 
show abnormalities and therefore, the neuronal plasticity of inhibitory networks may 
also be affected (Benes and Berretta, 2001; Daskalakis et al., 2007; Rajkowska et al., 
2007; Lanoue et al. 2010). 
Figure 9. The “neuroplastic” hypothesis of depression.  (A-E) In the healthy brain, information is processed in partially 
overlapping neural networks. (B-F) In depression, information processing in some networks may not function properly. 
Pyramidal neurons in the mPFC reduced their dendritic tree and spine number (C-G) Antidepressant treatment may 
enhance connectivity in neural networks. (D-H) Activity-dependent pruning of synapses selects out and stabilizes the active 
synapses and networks, and pyramidal neuron structure is then recovered. Illustrations based on Castren, 2004 and 2005, 
Radley et al., 2004. 
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PSA-NCAM is a good candidate to mediate these structural changes, 
especially in interneurons. In fact, ncam1 and st8siaII are candidate susceptibility 
genes for schizophrenia and a long standing record links disregulation of NCAM to 
the pathophysiology of several neuropsychiatric disorders (for review, Vawter, 2000; 
Brennaman and Maness, 2008). 
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The main objectives of this thesis are to study the influence of dopaminergic 
neurotransmission on the neuronal plasticity of prefrontocortical circuits and to 
evaluate whether changes in the expression of the polysialylated form of the neural 
cell adhesion molecule (PSA-NCAM) are responsible for these neuroplastic changes. 
From these two main objectives, derive the subsequent specific objectives: 
1. To map the distribution and analyze the morphology of PSA-NCAM expressing 
cells in the mPFC of adult rats. 
2. To map the distribution of PSA-NCAM expressing elements in the mPFC 
neuropil and to characterize the neurochemical phenotype of those elements 
located surrounding the soma of pyramidal neurons in this cortical region. 
3. To study the expression of D2R in PSA-NCAM expressing neurons in the 
mPFC, as well as the spatial relationship between these cells and 
dopaminergic terminals in this region. 
4. To analyze the effects of a lesion on the mesocortical dopamine pathway and 
the effects of chronic treatments with D2R agonists and antagonists on the 
expression of PSA-NCAM and other molecules related to synapses and 
inhibitory neurotransmission in the mPFC. 
5. To study in different time points the expression of plasticity-related genes in 
the mPFC during a chronic treatment with a D2R agonist. 
6. To evaluate the effects of the enzymatic depletion of PSA from NCAM on the 
remodeling of inhibitory networks and pyramidal neurons in the mPFC and its 
influence on the neuroplastic changes induced by chronic treatment with D2R 
agonists. 
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1. ANIMALS 
One hundred and fourteen male Sprague-Dawley rats (3 months-old, Harlan 
Interfauna Iberica S.L., Barcelona, Spain) were used in this doctoral thesis as follows: 
(i) 8 rats, to analyze the distribution PSA-NCAM expressing cells and neuropil; (ii) 4 
rats, to analyze the phenotype of PSA-NCAM expressing puncta surrounding 
pyramidal cell somata; (iii) 4 rats, to study the relationship between PSA-NCAM 
neurons and D2R or dopaminergic fibers; (iv) 10 rats, for the dopamine depletion 
experiment (6-OHDA lesion); (v) 10 rats, for the D2R antagonist treatment 
(haloperidol); (vi) 12 rats, for the D2R agonist treatment (PPHT); (vii) 36 rats, for 
PPHT treatment destined to gene expression study; (viii) 24 rats, for PPHT treatment 
after PSA depletion; and (ix) 6 rats, to confirm the specificity of primary antibodies by 
western blot analysis (figure 10). 
Transgenic mice pups [GIN, Tg (gad-GFP)-45704Swn] of postnatal day 8 (P8) 
were used for preparation of mPFC organotypic cultures. These animals express the 
green fluorescent protein (GFP) under the promoter of the gad gene (codifies the 
enzyme responsible for the synthesis of the inhibitory neurotransmitter GABA). Adult 
mice were purchased from Jackson laboratories (Bar Harbor, Maine, USA) and mice 
pups were obtained in our animal facility (figure 10). 
1.1. General housing conditions and bioethical issues 
Rats were housed in groups of three or four and were allowed to habituate to 
our facilities at least one week prior to the start of the experiments.  
Pregnant mice were housed alone and mice pups were kept with their mothers 
until being used. 
Animals were maintained in a temperature- and humidity-controlled 
environment and on a 12 h light/dark cycle with food and water available ad libitum.  
All animal experimentation was conducted in accordance with the Directives 
86/609/EEC and 2010/63/EU of the European Communities Council of November 
24th 1986 and September 22nd 2010, respectively, on the protection of animals used 
for scientific purposes and was approved by the Committee on Bioethics of the 
Universitat de València. Every effort was made to minimize the number of animals 
used and their suffering. 
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Figure 10.  Scheme summarizing the animals, treatments, procedures and analyses used in this thesis. 
Abbreviations: c.m., culture medium; i.c., intracranial injection; i.p., intraperitoneal injection; IHC, immunohistochemistry. 
For antibodies abbreviations, please see table 1 or the abbreviation list on page xviii-xix. 
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2. PHARMACOLOGICAL TREATMENTS IN VIVO 
2.1. 6-hydroxydopamine lesions of Ventral Tegmental Area 
Ten rats were pre-treated with the norepinephrine uptake blocker, desipramine 
hydrochloride [25 mg/kg in 0.9% NaCl, intraperitoneal (i.p; Sigma-Aldrich)] to prevent 
destruction of noradrenergic nerve terminals. Thirty minutes later, they were deeply 
anaesthetized (5 mg/g xylazine and 0.5 ml/kg ketamine i.p.) and placed in a 
stereotaxic instrument (David Kopf Instruments, Tujunga, CA). A 10 μl Flexifil tapertip 
syringe (World Precision Instruments Inc.; Sarasota, FL) was then positioned in the 
VTA using the following coordinates from the atlas of Paxinos and Watson (Paxinos 
and Watson, 2007): Bregma – 6.00 mm, Lateral ± 0.60 mm, Deep – 8.20 mm. The 
needle was left in position for 1 minute and then 2 μl of 6-hydroxydopamine 
hydrobromide (6-OHDA, Sigma-Aldrich, 2 µg/µl in 0.9% NaCl) were injected over a 2 
minutes period into one hemisphere. After the injection was completed, the needle 
was left in place for another 2 minutes to reduce reflux of the solution into the track of 
the injection needle and then withdrawn. The contralateral hemisphere was used as 
a control and received 2 μl of vehicle solution (0.9% NaCl) in the VTA following the 
same procedure. After recovery from anaesthesia, rats were returned to their cages 
in the colony room and were perfused transcardially 7 days later. The lesion of TH 
expressing somata in the VTA of the 6-OHDA injected hemisphere was confirmed by 
microscopic observation of a subset of sections processed for TH 
immunohistochemistry (see section 5.1 and figures 10 and 11). 
2.2. Haloperidol treatment 
Rats were randomly separated in 2 groups (n=5) and received either the D2R 
antagonist haloperidol (Sigma-Aldrich, 0.5 mg/kg/day in 0.1 N acetic acid, pH 5-6) or 
the vehicle solution (0.1 N acetic acid). Treatments were administered i.p. once daily 
for 26 consecutive days (MacDonald et al., 2005). Body weight was measured before 
the onset of the treatment (day 0), after 13 days of i.p injections and at the end of the 
treatment (day 26). Animals were perfused transcardially 24 hours after the last 
injection (figure 10). 
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2.3. PPHT treatment 
The selective D2R agonist 2-(N-Phenethyl-N-propyl) amino-5-hydroxytetralin 
hydrochloride (PPHT, Sigma-Aldrich, 1.5 mg/kg/day in 0.9% NaCl) was administered 
to 6 rats (treated group), once daily for 7 consecutive days (Sugahara and Shiraishi, 
1998). Rats from control group (n=6) received saline i.p. injections following the same 
procedure. Animals were weighted at the beginning (day 0), in the middle (day 4) and 
at the end (day 7) of pharmacological treatment, and were perfused transcardially the 
day after the last i.p. injection (figure 10).  
2.4. PPHT treatment for gene expression study 
Thirty-six rats were randomly assigned to 6 experimental groups (n=6) and 
were i.p. injected once daily either with PPHT (1,5 mg/kg/day in 0,9% NaCl; Sigma-
Aldrich) or saline (0,9% NaCl) for 1, 4 or 7 consecutive days. Body weight was 
measured before the onset of treatments, in the middle of the experiment and at the 
end, and rats were sacrificed by decapitation 24 hours after the last injection in order 
to obtain fresh tissue (figure 10). 
2.5. Endo-N and PPHT combined treatment 
Twenty-four rats were deeply anaesthetized and received unilaterally a 
stereotaxic injection (see section 2.1) of either the enzime Endo-N-
acetylneuraminidase (Endo-N; 1 μl; 369 U/μl in glycerol; AbCys, Paris, France) or the 
vehicle solution (1 μl; 0.9% NaCl  and glycerol 1:1) in the secondary motor cortex 
(Bregma + 1,70 mm, Lateral ± 1,00 mm, Deep – 0,80 mm; Paxinos and Watson, 
2007). The Endo-N is a phage enzyme that specifically cleaves α-2,8-linked N-
acetylneuraminic acid polymers with minimum chain length of 8 (see chapter 1, 
figure 7).  It diffuses rapidly throughout the brain and removes all detectable PSA 
within 1 day for 3-4 weeks (Vimr et al., 1984; Hallenbeck et al., 1987). The 
contralateral hemisphere did not receive any injection because pilot experiments 
demonstrated that Endo-N also diffuses to contralateral mPFC. 
Seven days later, rats which had received Endo-N (n=12) were randomly 
separated in 2 groups (n=6) and were administered intraperitoneally either PPHT or 
saline for 7 days as described in section 2.3. The same procedure was followed for 
rats which had received intracranial vehicle injection (n=12). Body weight was 
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measured in the day of surgery (day 0), before the onset of pharmacological 
treatment (day 7), in the middle of pharmacological treatment (day 10) and at the end 
of the experiment (day 14). Animals were perfused transcardially 24 hours after the 
last i.p. injection (figure 10). 
3. HISTOLOGICAL PROCEDURES 
3.1. Perfusion and microtomy techniques 
Rats, except those treated as described in section 2.4, were perfused 
transcardially under deep chloral hydrate anesthesia, first for 1 minute with NaCl 0.9 
% and then for 30 minutes with 4% paraformaldehyde in phosphate buffer (PB) 0.1 
M, pH 7.4. Thirty minutes after perfusion, brains were extracted from the skull and 
their hemispheres were separated. 
All brain hemispheres, except those destined to Golgi impregnation 
(contralateral hemispheres of rats described in section 2.5), were cryoprotected with 
30% sucrose in cold PB 0.1 M (4ºC) for 48 hours and then cut in 50 m-thick coronal 
sections with a freezing-sliding microtome (Leica SM2000R, Leica, Nussloch, 
Germany). Slices were collected in 10 subseries and stored at –20 ºC in a 
cryoprotective solution until used (30% glycerol, 30% ethylene glycol in PB 0.1M). 
Brain hemispheres destined to Golgi impregnation were washed in cold PB 0.1 
M (4ºC) for one day and then cut in 5-mm-thick coronal blocks. Two 50 m-thick 
coronal sections from all slices containing mPFC were obtained with a vibratome 
(Leica VT 1000E, Leica, Nussloch, Germany) in order to check whether Endo-N also 
diffused to contralateral mPFC (see section 5.1). Blocks were then impregnated by 
Golgi method as described below (see section 6). 
See a summarizing scheme in figure 10. 
3.2. Fresh tissue extraction and dissection of mPFC 
Rats treated as described in section 2.4 were sacrificed by decapitation using 
a guillotine. Brains were immediately removed from the skull and placed on Petri 
dishes filled with cold sterile PB. Under a stereo microscope (SZX7; Olympus) the 
overlying pia was removed and coronal cuts were made to remove portions of the 
rostral and caudal poles. The mPFC from the left and right cortices were dissected 
with a micro scalpel and then stored on separated eppendorfs. Tissue was frozen in 
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liquid nitrogen and kept at -80ºC until used. The whole procedure was performed at 
cold temperature and under RNAse-free conditions to prevent RNA degradation. 
4. MEDIAL PREFRONTAL CORTEX SLICE CULTURES 
4.1. Preparation of slice cultures 
P8 transgenic mice pups [GIN, Tg (gad-GFP) 45704Swn] were decapitated 
and their brains were removed from the skull under sterile conditions. Brains were 
placed into Petri dishes filled with cold (4º C) sterile dissecting medium [1% glucose 
(0.5 gr/mL, MERCK), 0,2% penicillin/streptomycin, 0,1% hexamycin, 0,5% L-
glutamin, 0,05% fungizone (GIBCO) in GBSS (Life Technologies)]. The overlying pia 
was gently removed and coronal cuts were made to remove portions of the rostral 
and caudal poles, leaving the frontoparietal region intact. The right and left cortices 
were cut simultaneously in the coronal plane at a thickness of 350 µm with a 
McIlwainTM Tissue Chopper. Slices were then transferred into dissecting medium and 
separated gently by agitation. 
Slices containing mPFC were placed on moistened translucent membranes of 
tissue culture inserts (0.4 μm, Millicell-CM, Millipore, Bedford, MA, USA) and 
immersed in 1 mL of Serum-OPTIMEM culture medium [25% heat inactivated horse 
serum,  25% HBSS, 50% Optimem-1 (GIBCO) supplemented with 10 µL/mL glucose 
(0,5 gr/mL, MERCK)]. Three slices were cultured in the same insert and six inserts 
were placed together in six-well plates. To ensure that slices from control and treated 
group were cultured under identical conditions, three inserts from each plate were 
designated as “control group” and other three, to “treated group”. 
Cultures were stored in a humid atmosphere at 36°C, in 5% CO2 for 14 days 
(HERAcell® 150i, Thermo Scientific) and culture medium was changed twice a week. 
4.2. Delivery of Endo-N 
After 12 days in vitro (DIV 12), 2 U/mL of the enzyme Endo-N was added to 
the culture medium in slices from treated group, whereas slices from control group 
received the same amount of vehicle solution (glycerol) in their culture medium. Two 
days before (DIV 14), slices were fixed as described below (section 4.3). 
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4.3. Histological processing of slices 
Slices were fixed by immerse the inserts for 30 minutes in a solution of 4% 
paraformaldehyde in 0.1M phosphate buffer (PB; pH 7.4) and then washed with PB 
intensively. Because pilot experiments had demonstrated that our mPFC slices used 
to decrease their thickness to 150-200 µm, tissue was not cut in thinner sections 
before being processed for the immunohistochemistry. 
In order to separate the slices that had been cultured in the same insert, insert 
membranes were cut surrounding each slice and then slices were stored at 4ºC fully 
immersed in PB 0.1M. 
5. IMMUNOHISTOCHEMICAL STUDY 
All the antibodies employed in this doctoral thesis and its dilutions and 
incubation conditions can be found in Table 1. For each experiment, all the studied 
sections passed through all procedures simultaneously to minimize any difference 
from immunohistochemical staining itself. To avoid any bias in the analysis, all slides 
were coded prior to the analysis and the codes were not broken until the experiment 
was finished. 
5.1. Immunohistochemistry for conventional light microscopy 
Tissue was processed "free-floating" for immunohistochemistry using the 
avidin-biotin-peroxidase (ABC) method as follows. Fifty µm-thick sections were first 
treated for 1 minute with an antigen unmasking solution (0.01 M citrate buffer, pH 6) 
at 100ºC. After cooling down sections to room temperature, they were incubated with 
3% H2O2 in phosphate buffered saline (PBS) for 10 minutes to block endogenous 
peroxidase activity. After this, sections were treated for 1 hour with 10% normal 
donkey serum (NDS; Jackson ImmunoResearch Laboratories, West Grove, PA) in 
PBS with 0.2% Triton-X100 (Sigma-Aldrich, St. Louis, MO) and then, they were 
incubated with the appropriate primary antibody (table 1) in PBS with 0.2% Triton-X-
100 and 5% NDS.  
Next, sections were incubated for 1 hour with the right biotinilated secondary 
antibody (table 1) in PBS with 0.2% Triton-X-100 and 5% NDS, followed by a 30 
minutes treatment with an avidin-biotin-peroxidase complex in PBS (ABC; Vector 
Laboratories, Peterborough, UK). Color development was achieved by incubating 
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with 3,3’- diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich) and 0.033% 
H2O2 for 4 minutes. 
Finally, sections were mounted on slides, dried for one day at room 
temperature, dehydrated with ascending alcohols and rinsed in xilol. After this, 
sections were coverslipped using Eukitt mounting medium. 
PSA-NCAM immunohistochemistry was performed in tissue from control rats 
(to describe PSA-NCAM expression in mPFC neuropil and cells) and from rats 
described in 2.1, 2.2, 2.3 and 2.5, to analyze effects of each treatment on PSA-
NCAM expression in the mPFC or the effectiveness of Endo-N (2.5). 
SYN and GAD67 immunohistochemistry was performed in brain sections from 
2.1, 2.2, 2.3 and 2.5 experiments, in order to study how treatments affected the 
mPFC neuropil expression of those proteins. 
Tissue from 2.1 experiment containing VTA, was processed for TH 
immunohistochemistry in order to confirm the lesion (figure 11). 
 
Brain sections from animals treated as described in 2.5 were processed for 
VGLUT1 immunohistochemistry to study the effect of the treatment on VGLUT1 
neuropil expression. 
A summarizing scheme of these procedures can be found in figure 10. 
5.2. Immunohistochemistry for confocal microscopy 
In general, tissue was processed "free-floating" for immunohistochemistry as 
described above (section 5.1) but omitting the endogenous peroxidase block. 
Sections were incubated with a cocktail of two, three or four primary antibodies and 
then with the appropriate fluorescent secondary antibodies (table 1). Finally, sections 
Figure 11.  (A,B) Microphotographs comparing the TH immunoreactivity in the Ventral Tegmental Area (VTA) of a 6-
OHDA-treated hemisphere (A and B, right) with its contralateral vehicle-treated (control) hemisphere (A and B, left). 
Observe a lower intensity in the 6-OHDA injected VTA when compared with the control VTA. Brain section. located at 
Bregma -5,00 mm (coordinates derived from the atlas of Paxinos and Watson, 2007) Scale bar: 250 μm. 
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were mounted on slides and coverslipped using DakoCytomation fluorescent 
mounting medium (Dako North America Inc., Carpinteria, CA). 
When it was necessary to use two primary antibodies generated in mouse in 
the same immunohistochemisty, sections were first processed for one of them 
(primary and secondary antibody) and next, they were incubated with the other 
primary antibody generated in mouse. After that, sections were treated for 2 h with an 
excess of unconjugated goat anti-mouse IgG Fab fragments (1:100; Jackson 
ImmunoResearch Laboratories, West Grove, PA) in order to be recognized before by 
an anti-goat fluorescent secondary antibody, avoiding crossing reactions (Lewis Carl 
et al. 1993). 
“Goat anti-mouse IgG subclass 1 specific” was used for the detection of anti-
CaMKII-α primary antibody when other primary antibody generated in mouse was 
also being used. Because this secondary antibody was conjugated with biotin, the 
Avidin, NeutrAvidin®, Texas Red® conjugate (1:200, Molecular Probes) or 
streptavidin, Alexa Fluor ® 488 conjugate were used before to detect biotin (see table 
1). 
To analyze the neurochemical phenotype of PSA-NCAM expressing puncta 
surrounding pyramidal neuron somata in the mPFC, triple immunostainings in brain 
sections from control rats were performed. PSA-NCAM and CaMKII-α (pyramidal 
neuron marker) were labeled in all of them and additionally markers of inhibitory 
elements (GAD65/67), synapses (SYN), inhibitory (VGAT) or excitatory (VGLUT1) 
synapses and interneuron subpopulations (PV, CR, CB). A quadruple 
immunostaining (CaMKII-α - PSA-NCAM - PV - SYN) was also performed in order to 
know whether perisomatic puncta co-expressing PSA-NCAM and PV corresponded 
to synapses. 
Brain sections from control rats were also used in order to study whether PSA-
NCAM neurons co-expressed dopamine D2R (PSA-NCAM – D2R – CB triple 
immunostaining) and whether they showed dopaminergic fibers close to their somata 
(PSA-NCAM – TH – DAT and PSA-NCAM – TH – SYN triple immunostainings). 
In tissue from rats described in section 2.5, we performed the following  
immunostainings: PSA-NCAM - PV - CB and PSA-NCAM - CR (to analyze the 
neurochemical phenotype of PSA-NCAM expressing neurons after treatment); 
CaMKII-α - PSA-NCAM, CaMKII-α - PV - SYN and CaMKII-α - MAP2 - GAD65/67 (to 
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study perisomatic and/or peridendritic innervations of mPFC pyramidal neurons after 
treatment). 
Medial prefrontal cortex slice cultures from Gad-GFP transgenic mice (section 
4) were immunostained as follows: PSA-NCAM – GFP (to check Endo-N efficiency 
and to study its effects on the density of dendritic spines in GFP expressing 
interneurons); VGAT – SYN – GFP and VGLUT1 – CB – GFP (to study the effects on 
the neuropil expression of these proteins); CaMKII-α – PV, CaMKII-α – SYN, CaMKII-
α – VGAT and CaMKII-α – VGLUT1) (to study perisomatic innervations of mPFC 
pyramidal neurons after treatment). 
See a summarizing scheme in figure 10. 
 
 
Table 1. Primary and secondary antibodies 
 
Primary antibodies 
(abbreviated names) 
  
 
 
 
 
 Host Isotype Dilution Incubation Company References 
       
Anti-CB Rabbit IgG 1:2000 O/N, 4ºC Swant Hédou et al., 2002 
Anti-CR Rabbit IgG 1:2000 O/N, 4ºC Swant Schwaller et al., 1993 
Anti-CaMKII-α Mouse IgG1 1:500 36 h, 4ºC Abcam Benson et al., 1992 
Anti-DAT Rat IgG2a 1:200 O/N, 4ºC Chemicon-Millipore Freed et al., 1995 
Anti-D2R Rabbit IgG 1:200 O/N, 4ºC Chemicon-Millipore Brock et al., 1992 
Anti-GAD67 Mouse IgG2a 1:500 O/N, 4ºC Chemicon-Millipore Varea et al., 2005 
Anti-GAD65/67 Rabbit IgG 1:1000 O/N, 4ºC  Chemicon-Millipore Benagiano et al.,  2007 
Anti-GFP Chicken IgY 1:1000 O/N, 4ºC Chemicon-Millipore Kain et al., 1995 
Anti-MAP2 Mouse IgG1 1:2000 O/N, 4ºC Sigma-Aldrich Riederer and Matus, 1985 
Anti-PSA-NCAM Mouse IgM 1:700 36 h, 4ºC Abcys Theodosis et al, 1991 
Anti-PV 
(1) 
 Rabbit IgG 1:2000 O/N, 4ºC Swant Miettinen et al., 1996 
Anti-PV 
(2)
 Guinea pig IgG 1:2000 36 h, 4ºC Synaptic Systems www.sysy.com 
Anti-SYN 
(3)
 Mouse IgG1 1:500 O/N, 4ºC Sigma-Aldrich Devoto and Barnstable, 1989 
Anti-SYN  Rabbit IgG 1:1000 O/N, 4ºC Chemicon-Millipore Hanaya et al., 2007 
Anti-TH Mouse IgG1 1:200 O/N, 4ºC Chemicon-Millipore Höckfelt et al., 1977 
Anti-VGAT Rabbit IgG 1:1000 O/N, 4ºC Synaptic Systems Takamori et al.,2000 
Anti-VLUT1 Guinea pig IgG 1:2000 O/N, 4ºC Chemicon-Millipore Melone et al., 2005 
       
      
Secondary antibodies 
     
 Host Label Dilution Incubation Company  
      
Anti-Chicken IgY Donkey DyLight
TM
488 1:400 1 h, 25ºC Jackson immunoResearch 
Anti-Guinea pig IgG Donkey Biotin-SP 1:400 1 h, 25ºC Jackson immunoResearch 
Anti-Guinea pig IgG Donkey Cy
TM
5 1:400 1 h, 25ºC Jackson immunoResearch 
Anti-Mouse IgM  Donkey Biotin-SP 1:400 1 h, 25ºC Jackson immunoResearch 
Anti-Mouse IgM  Goat Alexa Fluor® 555 1:400 1 h, 25ºC Molecular Probes 
Anti-Mouse IgG Donkey Biotin-SP 1:400 1 h, 25ºC Jackson immunoResearch 
Anti-Mouse IgG 
(4)
 Goat Unconjugated 1:100 2 h, 25ºC Jackson immunoResearch 
Anti-Mouse IgG1 
(4)
 Goat Biotin-SP 1:400 2 h, 25ºC Jackson immunoResearch 
Anti-Rabbit IgG Donkey Alexa Fluor® 488 1:400 1 h, 25ºC Molecular Probes 
Anti-Rabbit IgG Donkey Alexa Fluor® 647 1:400 1 h, 25ºC Molecular Probes 
Anti-Rat IgG Donkey Alexa Fluor® 488 1:400 1 h, 25ºC Molecular Probes 
Anti-Rat IgG Goat Alexa Fluor® 647 1:400 1 h, 25ºC Molecular Probes 
 
 (1)
 Used in CaMKIIα - PSA-NCAM - PV triple immunohistochemistry. 
(2)
 Used in CaMKIIα - PSA-NCAM - SYN- PV quadruple immunohistochemistry. 
(3)
 Used in SYN immunohistochemistry for light microscopy. 
(4)
 Used in multiple-labeling experiments for the detection of a primary antibody generated in mouse when other primary antibody generated in mouse was also being 
used. For instance, we have used anti-mouse IgG1 for the detection of anti-CaMKIIα and then, the Avidin-NeutrAvidin®- Texas Red® conjugate (1:200, Molecular 
Probes) or streptavidin-Alexa Fluor ® 488 conjugate were used before to detect biotin. 
Abbreviations: CB,  calbindin-D28k;  CR , calretinin;  CaMKIIα, α subunit of the Ca
2+
 /calmodulin dependent protein kinase II; DAT, dopamine transporter; D2R, 
dopamine D2 receptor; GAD67, 67 kDa isoform of the glutamate decarboxilase enzime, GAD65/67, both 65 and 67 kDa isoforms of the glutamate decarboxilase 
enzyme; GFP, green fluorescent protein; MAP2, Microtubule associated protein 2; PSA-NCAM, polysialylated form of de neural cell adhesion molecule; PV, 
parvalbumin; SYN, synaptophysin; TH, tyrosine hydroxylase; VGAT, vesicular γ-aminobutyric acid (GABA) transporter; VGLUT1, vesicular glutamate transporter 1. 
 
 
 
 43 Material and methods 
6. GOLGI METHOD 
In rats treated as described in section 2.5, contralateral hemispheres 
relatives to the side of the injection were cut into 5-mm thick coronal blocks (section 
3.1) and processed by Golgi-Colonnier method (Colonnier, 1964) with some 
modifications described before (Guirado et al. 2009). In brief, blocks were post-fixed 
with 3% potassium dichromate and 5% glutaraldehyde for 7 d at 4ºC and then 
impregnated with 0.75% silver nitrate solution for 48 hours. Blocks were then cut into 
150 μm-thick coronal sections with a vibratome, dehydrated with ascending alcohols 
and mounted with epoxy resin between two coverslips. 
To avoid any bias in the analysis, the slides were coded and the code was not 
broken until the analysis was completed. 
7. GENE EXPRESSION STUDY 
7.1. RNA isolation 
Frozen brain tissues from rats described in section 2.4 were homogenized in 
tubes containing TriPure reagent (Roche Applied Science, Indianapolis, IN) and total 
RNA was obtained by means of a one-step sample homogenization/lysis procedure. 
TriPure Isolation Reagent disrupted cells and denatured endogenous nucleases. 
Then, chloroform was added to the sample and the mixture was centrifuged. This 
step separates the sample into three phases: a colorless aqueous (upper) phase, a 
white interphase and a red organic (lower) phase. The upper phase was placed in a 
separate tube and RNA was recovered from it by isopropanol precipitation. Finally, 
RNA was isolated by alcohol precipitation steps.  
Purified total RNA was eluted in RNase-free water and stored at -80 ºC. RNA 
concentration and purity was measured in a spectrophotometer at 260 nm and 
260/280nm, respectively (Eppendorf BioPhotometer plus; Eppendorf AG, Hamburg, 
Germany). 
7.2. cDNA synthesis by RT-PCR 
Reverse transcription (RT) reactions were performed as follows: 2 µl oligo 
dTplus [10 pmol] were hybridized to 1 µl of total RNA (100ng/µl) in 10,5 µl volume by 
heating up to 65 ºC for 10 min. First strand cDNA was then synthesised by incubating 
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the hybridized RNA at 43 ºC for 60 min with dGTP, dTTP, dCTP, dATP (1 mM 
each),1 µl Expand reverse transcriptase (50 U/ µl), 0,5 µl Protector RNAse inhibitor 
(40 U/µl), 2 µl 1,4-dithio-DL-threitol (DTT, 100 mM) in 20 µl Buffer for Expand reverse 
transcriptase. All products were purchased from Roche Applied Science. cDNA 
reactions were then diluted fivefold in nuclease-free water. 
The quality of cDNA was checked by agarose gel electrophoresis after PCR 
amplification. Only the former small amplicon but not the latter larger amplicon was 
detected in all samples on the agarose gel electrophoresis, demonstrating no 
contamination of samples with genomic DNA (data not shown). 
7.3. DNA oligonucleotide primers 
Specific primers to rat gad67, gad65, ncam, st8siaII, st8siaIV and syn genes 
were designed from public sequences, which were obtained from Ensembl data base 
using “Primer 3” free software. Primers were designed between exons to avoid DNA 
contamination. The sequence of primers for the reference gene (ywhaz) was 
obtained from Bonefeld et al. 2008. See table 2, for further details. 
All DNA oligonucleotide primers were custom synthetized by Metabion 
international AG (Martinsried, Germany). 
 
Table 2. DNA oligonucleotide primers 
 
Rat target gene Primers Sequence (5’ →3’) Amplicon size
(1)
 
 
gad65 
 
Forward 
 
CTGCTTCTGGTTTGTACCTCCT 
 
122 
 Reverse CCATTGTGGTCCCATACTCC  
gad67 Forward CTGGAGCTGGCTGAATACCT 120 
 Reverse TCGGAGGCTTTGTGGTATGT  
ncam Forward AACGGACTCCAAACCATGAC 123 
 Reverse CTGGCTTTGCTTCTGACTCC  
st8siaII Forward GGCAACTCAGGAGTCTTGCT 123 
 Reverse GTCAGTCTTGAGGCCCACAT  
st8siaIV Forward CCTTCATGGTCAAAGGAGGA 125 
 Reverse CCAGTAACCTCTGACCGCAT  
syn Forward CTATGGGCAGCAAGGCTATG 120 
 Reverse CAGGCCTTCTCTTGAGCTCTT  
ywhaz Forward TTGAGCAGAAGACGGAAGGT 136 
 Reverse GAAGCATTGGGGATCAAGAA  
(1)
 Amplicon length in base pairs. 
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7.4. Real-time quantitative RT-PCR 
The amplification reactions were performed in triplicate in 10 µl SYBR Green 
PCR master mix 2X (Applied Biosystems), 4 µl cDNA (50ng) and 1 µl forward and 
reverse primers (240 nM each; see table 2) and 5 µl of water for a total volume of 20 
µl. The termocycler was an ABI PRISM 7700 Sequence Detector (Applied 
Biosystems). The cycling parameters were 95 ºC 15 s, 60 ºC 1 min for 40 cycles, 
after one initial step at 95 ºC, 10 min, which was set to activate the AmpliTaq Gold 
polymerase. 
Ct (cycle threshold) values were calculated by the StepOne Software v2.0 
(Applied Biosystems) from fluorescence readings, and these values were converted 
into copy number per copy number of reference gene (ywhaz). Primer specificity was 
checked by analyzing the dissociation curve method according to the Applied 
Biosystems protocol. 
8. ANALYSIS OF RESULTS 
8.1. Body weight analysis 
In rats described in sections 2.2-2.5, body weight differences across the 
different time points were calculated, and data were analyzed by unpaired Student’s 
t-tests or one-way ANOVA tests followed by multiple pair-wise comparisons with 
Bonferroni’s correction. 
8.2. Quantification of neuropil immunoreactivity 
This study was performed in brain sections from rats treated as described in 
sections 2.1, 2.2, 2.3 and 2.5 and processed for PSA-NCAM, SYN, GAD67 or 
VGLUT1 immunohistochemistry for conventional light microscopy (section 5.1) in 
order to analyze treatment effect on the neuropil expression of those proteins. 
From each immunostaining, three sections per animal were selected randomly 
from the following coordinate intervals [IL: Bregma 2.70 to 2.20 mm; PrL: Bregma 
3.70 to 2.20 mm; Cg: Bregma 1.70 to -0.26 mm (Paxinos and Watson, 2007)]. 
Sections were examined with an Olympus CX41 microscope under bright-field 
illumination, homogeneously lighted and digitalized using a CCD camera. 
Photographs to the different areas and layers were taken at 20X magnification. A 
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Nissl stain in alternate series of sections was used for determining layer and area 
boundaries within mPFC regions, based on cytoarchitectural differences across these 
layers and areas (figure 12). 
 
 
Grey levels were converted to optical densities (OD) using Image J software 
(NIH). Means were determined for each experimental group and data were subjected 
to paired Student’s t-test followed by Bonferroni’s correction (6-OHDA experiment, 
section 2.1) or to repeated-measures ANOVA (for the rest of experiments) using the 
SPSS software package (version 17). 
In repeated measures ANOVA, region (IL, PrL, Cg1 and Cg2) and layer (I, II, 
III, V, VI) were considered as within-subjects variables (repeated measures variables) 
and treatment (Haloperidol, Control; PPHT, Control; Endo-N/PPHT, Endo-N/Control 
Control/PPHT, Control/Control), as between-subjects variable. The sphericity 
assumption in repeated measures variables and the homogeneity of variances in 
between-subjects variable were first assessed by means of the Mauchly’s test of 
sphericity and the Levene’s test for homogeneity of variances. Levene’s test 
indicated that there were homogeneity of variances in between-subjects variable 
(p>0.05) in all cases. The assumption of sphericity in repeated measures variables 
(Mauchly's test) was violated (p<0.05) for the main effect of layer and for the region x 
Figure 12.  Panoramic and detailed views of the rat cingulate cortex showing the distribution of PSA-NCAM (B, F), 
SYN(C, G), GAD67 (D, H) and VGLUT1 (E, I) immunoreactivity in the neuropil. (A) A Nissl stain (cresyl violet) is used for 
determining layer boundaries within mPFC regions, based on cytoarchitectural differences across these layers. (F) Detailed 
view of PSA-NCAM immunoreactivity in layer I and II of the rat cingulate cortex. PSA-NCAM expressing neurons can be 
observed in layer II. Detailed view of (F) SYN GAD67 (G) and VGLUT1 immunoreactivity in layer III of the cingulate cortex. 
Scale bars: 250 μm for A-E and H-I; 20 μm for F-I. Roman numbers indicate cortical layers. 
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layer interaction for PSA-NCAM, SYN, GAD67 and VGLUT1 neuropil 
immunoreactivity, as well for the main effect of region for PSA-NCAM, GAD67 and 
VGLUT1. Therefore, degrees of freedom on the univariate repeated measures 
ANOVA test were adjusted using Greenhouse-Geisser correction for those variables. 
For all protein neuropil expression, ANOVA test showed significant main effects of 
treatment, region and layer (p<0.05, see results section), so multiple pair wise-
comparisons with Bonferroni’s correction were performed for each immunostaining in 
order to evaluate treatment effect on mPFC. The three-way interaction (region x layer 
x treatment) on the repeated measures ANOVA test was also significant for all 
protein neuropil expression (p<0.05, see results section). Multiple pair-wise 
comparison with Bonferroni’s correction were performed in each case, in order to 
analyze in which specific layer from each region inside the mPFC there were 
differences between groups (see results section). 
8.3. Estimation of the total number of PSA-NCAM expressing somata 
This quantification was performed in brain sections from the Endo-N/PPHT 
combined treatment experiment (section 2.5) processed for PSA-NCAM 
immunohistochemistry for conventional light microscopy (section 5.1). Since Endo-N 
intracranial injection results in an absolute absence of PSA-NCAM immunoreactive 
neurons in the mPFC (see figure 49 in chapter 6, section 1.2), only non-Endo-N 
injected animals were analyzed. 
The number of PSA-NCAM expressing neurons within the different layers and 
regions of mPFC was estimated using a modified version of the fractionator method 
(West, 1993), as described before (Nacher et al. 2002; Varea et al. 2007a). PSA-
NCAM expressing somata covering 100% of the sample area were counted, that is, 
within each 50 µm-thick section, all labeled cells found in the selected region 
(infralimbic, prelimbic, dorsal cingulate and ventral cingulate cortices) and layer (I, II, 
III, V and VI). The fractionator sampling scheme refers to the methodology of 
examining one out of every ten brain sections. Thus, our modification of the optical 
dissector combined with a 1:10 fractionator sampling is truly a modification of the 
optical fractionator method. One from 10 systematic-random series of sections 
covering the whole rostral to caudal extension of mPFC was viewed on an Olympus 
CX41 microscope. Cell somata were identified and counted with a 40X objective. 
Cells appearing in the upper focal plane were omitted to prevent counting cell caps.  
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Means were determined for each experimental group (Control/PPHT, 
Control/Control) within each region and layer from the mPFC area.  The normality of 
the variables and homogeneity of variances were first assessed by means of the 
Shapiro-Wilk´s normality test and the Levene’s test for homogeneity of variances. 
These tests showed that all the variables followed a normal distribution (p > 0.05) 
and all samples had equal variances (p>0.05). Data were then subjected to unpaired 
Student’s t-test statistical analysis followed by Bonferroni’s correction. 
8.4. Observation and quantification of multiple-labeled fluorescent cells 
Sections double or triple labeled for PSA-NCAM and different markers (section 
5.2) were observed under a confocal microscope (Leica TCS-SPE) using a 63X oil 
objective. PSA-NCAM expressing cells were first identified using conventional 
fluorescence microscopy and then, z-series of optical sections (1 µm apart) covering 
all its three-dimensional extension were obtained using sequential scanning mode.  
These stacks were processed with LSM 5 image software. In each immunostaining, 
fifty PSA-NCAM immunoreactive neurons per animal inside the mPFC [from Bregma 
+ 3,20 mm to - 1,40 mm (Paxinos and Watson, 2007)] were randomly selected to 
determine the co-expression of PSA-NCAM and each marker. Percentages of co-
localization were determined for each animal and means ± S.E.M. were calculated. 
In tissue from animals described in section 2.5., the data were subjected to 
unpaired Student’s t-test statistical analysis (Control/PPHT vs. Control/Control) 
followed by Bonferroni’s correction. 
8.5. Quantification of perisomatic/peridendritic puncta of mPFC pyramidal 
neurons 
8.5.1.  Co-localization of perisomatic PSA-NCAM expressing puncta and different 
markers 
Sections triple or quadruple labeled for CaMKII-α, PSA-NCAM and different 
markers (section 5.2) were mainly observed as described above (section 8.4) but 
with some differences. From each animal and immunostaining, fifty CaMKII-α 
expressing neurons from mPFC layers III and V and displaying triangular-shaped 
soma were randomly selected by conventional fluorescence microscopy. Z-series of 
optical sections (0.5 μm apart) were acquired using sequential scanning mode and 
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stacks were processed with LSM 5 Image Browser software at 4X-Zoom 
magnification. The soma profile of these neurons was drawn and puncta placed 
within an area 0.5 μm distal from the edge of this profile were analyzed. A puncta 
was defined as having an area not smaller than 0.15 and not larger than 2.5 μm2 (Di 
Cristo et al., 2007). The co-localization of PSA-NCAM and each of the different 
markers was analyzed on five consecutive confocal planes from each selected 
neuron, in which the penetration of both antibodies was optimal. The percentage of 
puncta co-expressing PSA-NCAM and each marker was obtained for each neuron 
and mean ± S.E.M was determined. Puncta density values were also determined for 
each marker and expressed as number of puncta per micron of soma perimeter. 
8.5.2. Analysis and comparison of perisomatic puncta density after Endo-N/PPHT 
combined treatments or Endo-N delivery in vitro 
For this purpose, we used brain sections from rats treated with Endo-N and/or 
PPHT (section 2.5) or slices from mPFC organotypic cultures (section 4), which were 
triple immunostained for CaMKII-α and other markers (see 5.2). Tissue was observed 
and analyzed as described above (8.5.1) but in this case, six pyramidal neurons per 
slice were analyzed as we will describe below for other analyses. 
Values of puncta density for PSA-NCAM, GAD65/67, PV, SYN or VGAT were 
obtained from each neuron and expressed as number of puncta per micron of soma 
perimeter. For each experimental group, mean ± S.E.M. was determined and the 
resulting values were analyzed by one-way ANOVA with the number of neurons as 
the “n”. Significant effects were further analyzed by Student-Newman-Keuls post-hoc 
test. In Endo-N and/or PPHT treated animals, the percentage of PV puncta co-
expressing SYN was also obtained from each neuron and analyzed following the 
same procedure. 
8.5.3. Analysis and comparison of GAD65/67 peridendritic puncta density after 
Endo-N / PPHT treatments. 
In general, GAD65/67 immunoreactive puncta were observed and analyzed as 
described before (section 8.5.2) but in this case, neurons should follow these 
features in order to be suitable for the study: (i) they must express both CAMKII-α 
and MAP2, (ii) their soma shape must be unequivocally pyramidal (iii) we should be 
able to follow clearly the apical dendrite until 200 μm from the soma. The profile of 
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these apical dendrites was drawn and puncta were counted using LSM 5 Image 
Browser Software as described above (section 8.5.1). Values of puncta density were 
expressed as the number of puncta per micron of dendrite length. For each 
experimental group, mean ± S.E.M. was determined and the resulting values were 
analyzed by one-way ANOVA with the number of neurons as the “n”. Significant 
effects were further analyzed by Student-Newman-Keuls post-hoc test. 
8.6. Analysis of dendritic spine density in mPFC pyramidal neurons after 
Endo-N / PPHT treatments 
Dendritic spine density was analyzed following a previously described 
methodology (Magariños et al., 1996; Guirado et al. 2009) in rat tissue processed by 
Golgi-Colonnier method (section 6). From each animal, six pyramidal neurons from 
layers III and V inside mPFC area were randomly selected. In order to be suitable for 
dendritic spine analysis, neurons should follow these features: (i) they must display 
complete Golgi impregnation of the apical dendrite, (ii) the cell type must be 
identifiable and (iii) the minimum length of the apical dendrite must be 200 μm from 
the soma. Each neuron was traced at 1000x magnification using a light microscope 
with a camera lucida drawing tube attachment (Nikon, Japan) and spines were 
quantified in four successive segments of 50 μm distances up to a total length of 200 
μm. Overall spine density values or densities per segment were expressed as 
number of spines/μm length. For each experimental group, mean ± S.E.M. was 
determined and the resulting values analyzed by one-way ANOVA with the number of 
neurons as the “n”. Significant effects were further analyzed by Student-Newman-
Keuls post-hoc test. 
8.7. Analysis of dendritic spine density in cultured GAD-GFP expressing 
interneurons after Endo-N delivery in vitro 
From each slice, six GFP-expressing neurons located in mPFC layer III were 
examined by confocal microscopy at 100X magnification. In order to be analyzed, 
neurons had to fulfill the following features: (1) the measured dendrite must not be 
truncated, (2) dendrite length must be greater than 180 μm, and (3) the soma must 
be located at least 30 μm deep from the surface of the tissue. These cells were first 
identified using conventional fluorescence microscopy and then, Z-series of optical 
sections (0.1 μm apart) covering all its three-dimensional extension were acquired 
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using sequential scanning mode. Stacks were processed with LSM 5 Image Browser 
software at 4X-Zoom magnification and spines were quantified in three successive 
segments of 60 μm distances up to a total length of 180 μm. Spine density values 
(overall or per segment) were expressed as number of spines/μm length. For each 
experimental group, mean ± S.E.M. was determined and the resulting values were 
analyzed by unpaired Student’s t-test with the number of neurons as the “n”. 
8.8. Estimation and comparison of neuropil puncta density after Endo-N 
delivery in vitro 
The density of neuropil puncta expressing Gad-GFP, VGAT, VGLUT1, SYN or 
CB was analyzed in mPFC, layer III. From each immunostaining, slices from the 
same rostral-caudal level were examined under a confocal microscope (Leica TCS 
SPE) using a 100X oil objective. Z-series of optical sections (0.5 μm apart) were 
obtained using sequential scanning mode and processed with LSM 5 Image 
software. The values of acquisition settings, such as the laser intensity percentage, 
gain and offset were identical for each stack taken from the same area. 
Subsequently, confocal images, in which the same level of antibody penetrability was 
observed, were chosen from each stack. Then, the background fluorescence of each 
image was subtracted. Due to the density and proximity of puncta, these were 
divided into three size groups: from 4 to 22 pixels, from 23 to 33 pixels and from 34 to 
infinite. This last group was not taken into account, since it only represented fibrillar 
processes. Then, images were normalized and thresholded and puncta were counted 
automatically using ImageJ software. All slides were coded prior to analysis and the 
codes were not broken until the experiment was finished. Means ± S.E.M were 
determined for each experimental group and data were subjected to unpaired 
Student’s t-test. 
8.9. Gene expression data analysis 
The analysis of gene expression in rats treated as described in 2.4, was 
performed by means of the “2-CT method” (Livak et al., 2001) where, 
∆∆CT = (CT,target gene - CT, reference gen)exp. group - (CT,target gene - CT, reference gen)control group 
The resulting values were subjected to one-way ANOVA with Bonferroni’s 
correction. 
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9. SPECIFICITY OF PRIMARY ANTIBODIES 
The specificity of all the primary antibodies employed in our study has been 
tested and confirmed by their commercial providers using western blot analysis of rat 
brain homogenates. In addition, the commercial providers and/or previous studies 
have tested them by immunohistochemistry in paraformaldehyde fixed rat brains (see 
references on table 1). All these antibodies showed a regional and cellular 
immunolabeling distribution comparable to that of their respective antigens with the 
same or other equally selective antisera. In order to confirm that some of the 
immunostaining was not produced by the secondary antibodies or by the 
immunohistochemical protocol, we have omitted primary antibodies or have 
substituted them by normal donkey serum. These controls resulted in a complete 
absence of immunostaining in every case. 
In addition, we performed western blot analysis to confirm the specificity of the 
primary antibodies used for neuropil immunoreactivity quantification (figure 13). Six 
male Sprague-Dawley rats (3 months old) were sacrificed by decapitation, their 
brains were removed and their mPFC were dissected out. Samples were immediately 
frozen in liquid nitrogen and kept at -80ºC until use.  For protein extraction, tissue 
was homogenized in 1% NP40, 0.1% SDS, 0.5% Sodium deoxycholate, 150 mM 
NaCl and 50 mM Tris-HCl (pH 8.0) containing a mixture of protease inhibitors 
(Sigma). Samples were kept in rotation at 4ºC for 2 hours and then, centrifugated at 
12000 rpm and 4ºC for 20 minutes. Supernatant was assessed for the amount of 
protein using Bradford reagent (Sigma) at 595 nm with BSA as the standard. Protein 
extract was boiled for 1 minute in reducing electrophoresis buffer and then, samples 
containing 20 μg of protein were resolved on 8% (for PSA-NCAM western blot) or 
10% (for SYN and GAD67 western blot) SDS-polyacrylamide gels at 32 mA, 250 V 
for 2 hours. Prestained broad-range protein ladders (Fermentas International Inc, 
Canada, USA) were included to measure molecular weight of individual bands. The 
proteins were transferred overnight at 20 V, 350 mA at 4ºC onto nitrocellulose sheets 
(BioRad Laboratories, Hercules, CA, USA). After saturation of the nonspecific sites 
with 5% non-fat dry milk in TBS-T (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% 
Tween-20), the blots were incubated at room temperature for 2 hours with antisera 
directed against PSA-NCAM (1:1000), SYN (1:2000) or GAD67 (1:1000). Membranes 
were then washed and incubated with horseradish peroxidase-conjugated goat anti-
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mouse IgM (1:3000; Sigma) or goat anti-mouse IgG (1:2500; Sigma), respectively, in 
blocking buffer for 1 h at room temperature. Immunoreactive bands were detected 
with the enhanced chemiluminescence system, ECL (Amersham Pharmacia, 
Piscataway, NJ, USA) exposing later the blots to Kodak XAR-5 film (Sigma). Control 
for PSA-NCAM western blot (lane 2) was performed treating samples containing 20 
μg of mPFC protein with 1 μl of EndoN (Abcys). Controls for SYN and GAD67 
immunoblotting (lane 2) were carried out using the same amount of total protein 
isolated from rat liver tissue instead of mPFC tissue. Since PSA-NCAM western blot 
rendered a wide band probably due to different polysialylation levels, we have also 
tested the specificity of the anti-PSA antibody using sections from control male rats 
injected intracerebrally with EndoN (Abcys), an enzyme that depletes exclusively 
PSA from NCAM. In these sections, no immunostaining could be detected in the 
mPFC. 
 
Figure 13. Representative immunoblots of total 
protein isolated from rat mPFC tissue (lane 1) 
showing specific immunoreactivity for (A) PSA-
NCAM, (B) SYN and (C) GAD67. Molecular weight 
markers are indicated, and demonstrate that the 
observed bands migrate at the expected weight of 
approximately (A) 180–220°kDa for PSA-NCAM, 
(B) 38 kDa for synaptophysin and (C) 67 kDa for 
GAD67. Lane 1 = 20 μg of rat mPFC total protein; 
lane 2 (A) = 20 μg of rat mPFC total protein treated 
with 1 μl of Endo-N; lane 2 (B, C) = 20 μg of total 
protein isolated from rat liver tissue. 
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1. PSA-NCAM EXPRESSING CELLS IN THE ADULT mPFC 
1.1. Distribution and morphology of PSA-NCAM expressing cells 
PSA-NCAM expressing somata were found in all the regions [Infralimbic cortex 
(IL), prelimbic cortex (PrL), dorsal cingulate cortex (Cg1) and ventral cingulate cortex 
(Cg2)] and all the layers (I, II, III, V and VI) of the mPFC (figure 14). They were more 
abundant in deep layers (V-VI) than in layers II–III and their presence in layer I was 
scarce. 
 
PSA-NCAM expressing cells from layer I, were middle-sized (soma diameter 
aprox. 20 µm) with a rounded soma. In layers II and III, two types of PSA-NCAM 
immunoreactive cells could be observed: a) frequently found small cells (soma 
diameter < 20 µm) with fusiform morphology and b) scarce large cells (soma 
diameter 30–40 µm), frequently multipolar, showing immunoreactivity in their somata 
and proximal processes (figure 14 A, B). In layers V and VI, there were also two 
types of PSA-NCAM immunoreactive cells: a) scarce large multipolar cells (similar to 
those described in layer III), and b) more abundant small cells showing only a single 
process (figure 14 C, D). Large cells were found mainly in layer V, whereas small 
cells appeared equally in layer V and VI. All the regions of mPFC showed this cellular 
E 
Figure 14. Morphology (A-D) and distribution (E) of PSA-NCAM expressing cells 
in the mPFC of adult rats. (A) Big multipolar neuron in the cingulate cortex layer II. (B) 
Big multipolar neuron in the cingulate cortex layer III. (C) Small neuron in cingulated 
cortex layer V. (D) Unipolar neurons in prelimbic cortex layer VI. Scale bar: 20 µm. (E) 
Diagram showing the distribution and relative amount of PSA-NCAM expressing cells in 
different regions of the mPFC. Each dot correspond to three labeled cells. The number 
of cells is the mean of three sections from three different animals. Abbreviations: Cg1, 
dorsal cingulate cortex; Cg2, ventral cingulate cortex; IL, infralimbic cortex; PrL, 
prelimbic cortex. 
A B 
C D 
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distribution pattern. The only difference among regions was the presence of a layer of 
highly stained big cells in the upper limit of layer V in the infralimbic cortex. Big 
multipolar cells resembled those described in the piriform cortex layer III (Nacher et 
al., 2002a) and the hippocampal “non-granule” PSA-NCAM immunoreactive neurons 
(Nacher et al., 2002c). 
Confocal microscopic analysis showed that PSA-NCAM immunoreactivity in 
cells was located in the periphery and appeared absent from the central region of the 
cytoplasm and the nucleus (please, see figure 16 C, D1-2, F1-3 in section 2.2). 
2. PSA-NCAM EXPRESSION IN THE mPFC NEUROPIL 
2.1. Distribution of PSA-NCAM expression in the neuropil 
In the PrL and IL cortices the intensity of PSA-NCAM neuropil staining was 
higher than that of the Cg1 and Cg2 cortices. 
All regions within the mPFC showed a moderate intensity of staining in layer I, 
nearly lack of staining in layer II, weak staining in layer III and intense staining in 
layers V–VI (figure 15). 
 
 
Figure 15. Panoramic views of the rat 
cingulated cortex showing the 
laminated distribution of PSA-NCAM 
expression in the neuropil. (A) Cresyl 
violet staining. (B) PSA-NCAM 
immunostaining, showing a moderate 
intensity of staining in layer I, nearly lack 
of staining in layer II, weak staining in 
layer III and intense staining in layers V–
VI. Roman numbers indicate cortical 
layers. Scale bar: 250 μm. 
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2.2. Pyramidal neuron somata are surrounded by PSA-NCAM expressing 
puncta 
Pyramidal neurons in the mPFC of adult rats do not express PSA-NCAM 
(Gomez-Climent et al. 2010) but some PSA-NCAM expressing puncta, particularly in 
layers III and V, were found delineating the profiles of the soma and the juxtasomatic 
portion of the principal apical dendrite of mPFC pyramidal neurons. The mean 
density of these puncta was 0.368 ± 0.014 puncta/µm of soma perimeter (figure 16). 
 
Figure 16. PSA-NCAM immunos-
taining in interneurons and 
surrounding pyramidal neurons in 
the rat cingulate cortex, layer V. 
(A)  Pyramidal neuron, conventional 
optical microscopy with DAB 
immunostaining. Note the presence 
of several immunoreactive puncta 
surrounding non-labeled somata. (B) 
Pyramidal neuron, laser confocal 
microscopy with fluorescent 
immunostaining. B1 is a single 
confocal plane where the soma 
shows CAMKII expression (a marker 
of principal neurons), and it is 
surrounded by external PSA-NCAM 
immunoreactive puncta. B2 is a 2D 
projection of ten consecutive focal 
planes located 0.5 μm apart. (C & D) 
For comparative purposes we also 
show microphotographs of a PSA-
NCAM expressing neuron in the 
cingulate cortex, as revealed with 
conventional optical microscopy with 
DAB immunostaining (C) and laser 
confocal microscopy with fluorescent 
immunostaining (D). D1 is a single 
confocal plane and D2 is a 2D 
projection of ten consecutive focal 
planes located 0.5 μm apart. (E & F) 
Three selected consecutive confocal 
planes from the 2D projections 
shown in B2 and D2 respectively. 
Scale bar: 10 μm for A, B, D and F; 
6.5 μm for C and 11.5 μm for E. 
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2.2.1. Most PSA-NCAM expressing perisomatic puncta on mPFC pyramidal neurons 
express inhibitory or synaptic markers 
PSA-NCAM expressing perisomatic puncta mainly co-expressed markers of 
inhibitory elements or synapses, such as GAD65/67 (36.073 ± 2.704%; table 3, 
figure 17 A) or VGAT (38.363 ±1.005%; table 3, figure 17 B) and rarely co-
expressed VGLUT1 (2.545±0.461%; table 3, figure 17 C), a marker of excitatory 
synapses. The synaptic vesicle protein SYN was also frequently found in PSA-NCAM 
expressing perisomatic puncta (34.338 ± 1.858%; table 3, figure 17 D). 
Because PSA-NCAM expressing perisomatic puncta were shown to be mainly 
inhibitory, the co-expression in these puncta of the interneuron subpopulation 
markers PV, CR and CB was also studied. This analysis revealed that the highest 
percentage of co-localization occurred with PV (40.621 ± 1.469%; table 3, figure 18 
A), whereas the co-localization with CR (2.890 ± 0.087%; table 3, figure 18 C) or CB 
(2.415 ± 0.039%; table 3, figure 18 D) was very low. The density of PV expressing 
perisomatic puncta was substantially higher than that of puncta expressing CB or CR 
(see table 3). 
In order to know whether perisomatic puncta co-expressing PSA-NCAM and 
PV corresponded to synapses, we analyzed the co-localization of these molecules 
with SYN. Surprisingly, despite the high percentage of co-localization of PSA-NCAM 
with either PV or SYN in the perisomatic region (see above) and the high density of 
puncta co-expressing PV and SYN (table 3), only 1.990 ± 0.138 % of PSA-NCAM 
puncta co-expressed both PV and SYN (table 3, figure 18 B2). These triple labeled 
puncta were present in a very low density (0.007± 0.001puncta/µm of soma 
perimeter; table 3). 
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Table 3. Puncta surrounding pyramidal neurons somata in the mPFC 
 
Puncta immunoreactive 
for: 
Puncta density 
(puncta/µm)
(a)
 
Co-localization  
percentage (%)
(b)
 
   
PSA-NCAM 0.368 ± 0.014  
GAD65/67 0.330 ± 0.040  
VGAT 0.565 ± 0.003  
VGLUT1 0.171 ± 0.006  
SYN 0.604 ± 0.072  
CB 0.027 ± 0.001  
CR 0.052 ± 0.008  
PV 0.402 ± 0.021  
PV– SYN 0.319 ± 0.017  
PSA-NCAM – GAD65/67 0.093 ± 0.018 36.073 ± 2.704 
PSA-NCAM – VGAT 0.184 ± 0.006 38.363 ± 1.005 
PSA-NCAM – VGLUT1 0.004 ± 0.001 2.545 ± 0.461 
PSA-NCAM – SYN 0.163 ± 0.013 34.328 ± 1.858 
PSA-NCAM – CB 0.010 ± 0.001 2.415 ± 0.039 
PSA-NCAM – CR 0.010± 0.001 2.890 ± 0.087 
PSA-NCAM –PV 0.179 ± 0.004 40.621 ± 1.469 
PSA-NCAM – PV – SYN  0.007± 0.001 1.990 ± 0.138 
GAD65/67 – PSA-NCAM 0.093 ± 0.018 28.114 ± 2.891 
VGAT – PSA-NCAM 0.184 ± 0.006 32.948 ± 0.869 
VGLUT1 – PSA-NCAM 0.004 ± 0.001 1.923 ± 0.423 
SYN –PSA-NCAM 0.163 ± 0.013 26.831 ± 0.908 
CB – PSA-NCAM 0.010 ± 0.001 42.977 ± 3.690 
CR – PSA-NCAM 0.010± 0.001 20.624 ± 1.122 
PV – PSA-NCAM 0.179 ± 0.004 43.331 ± 3.622 
 
(a)
 Puncta density data are expressed as mean ± s.e.m. of puncta expressing the named 
marker/s per micron of soma perimeter. 
(b)
 Co-localization percentage of puncta expressing the first named marker which also expresses the second or second and 
third named marker/s (i.e. PSA-NCAM – GAD65/67 co-localization percentage: percentage of PSA-NCAM expressing puncta 
which also express GAD65/67). Data are expressed as mean± s.e.m. 
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Figure 17. Confocal microscopic analysis of the neurochemical phenotype of PSA-NCAM immunoreactive puncta 
surrounding pyramidal cell somata in mPFC. (A) PSA-NCAM-expressing puncta co-localizing with GAD67 in the 
perisomatic region of CaMKII-α expressing neurons. (B) PSA-NCAM / VGAT double-labeled puncta surrounding CaMKII-α 
immunoreactive neurons. (C) Lack of co-localization between perisomatic PSA-NCAM-expressing puncta and VGLUT1-
expressing puncta. (D) Perisomatic puncta co-expressing PSA-NCAM and SYN. All the images in this figure are taken from 
single confocal planes. Scale bar: 10 μm. Insets in the images are 5X enlargements of puncta marked with arroheads. 
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Figure 18. Confocal microscopic analysis of the co-expression of PV, CR and CB in PSA-NCAM immunoreactive 
puncta surrounding pyramidal cell somata in mPFC. (A) PSA-NCAM-expressing puncta co-localizing with PV 
immunoreactive puncta in the perisomatic region of a neuron expressing CaMKII-α. (B) Very few perisomatic PSA-NCAM 
immunoreactive puncta co-expressed both PV and SYN. (C) PSA-NCAM immunoreactive puncta co-expressing CR 
surrounding CaMKII-α expressing neurons. (D) Observe a CB-expressing puncta close to a PSA-NCAM expressing puncta 
in the perisomatic region of a pyramidal neuron. All the images in this figure are taken from single confocal planes. Scale bar: 
10 μm. Insets in the images are 5X enlargements of puncta marked with arrowheads. 
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3. RELATIONSHIP BETWEEN PSA-NCAM EXPRESSING NEURONS AND 
DOPAMINERGIC INNERVATION IN THE ADULT mPFC 
 
3.1. PSA-NCAM expressing interneurons co-express dopamine D2 receptors 
Confocal microscopic analysis of brain sections triple immunostained for PSA-
NCAM, dopamine D2 receptors (D2R) and calbindin (CB) revealed that 76 ± 3 % of 
PSA-NCAM immunoreactive cells in the mPFC co-expressed the D2R. Moreover, 86 
± 4 % of these double labeled cells were calbindin expressing interneurons (figure 
19 A1-4). 
3.2. Dopaminergic fibers in the mPFC are closely apposed to PSA-NCAM 
expressing neurons 
In order to analyze the spatial relationship between PSA-NCAM expressing 
neurons and dopaminergic terminals in the mPFC, we performed a double 
immunohistochemistry for PSA-NCAM and Tyrosine hydroxylase [TH, the enzyme 
that catalyzes the conversion of the amino acid tyrosine to L-dihydroxy-phenylalanine 
(L-DOPA), the precursor for dopamine, which, in turn, is a precursor for 
norepinephrine]. Fibers containing TH were denser in layers I-III and they were 
sparse in the inner layers. Many TH immunoreactive fibers and puncta were 
observed in close apposition to PSA-NCAM expressing neurons (figure 19 B & C). 
Triple immunohistochemistry for PSA-NCAM, TH and SYN revealed that some of 
these PSA-NCAM/TH immunoreactive puncta also expressed SYN (figure 19 D & 
E). 
Because TH expressing fibers could be dopaminergic or norepinephrinergic 
(see TH definition above), a triple immunostaining for PSA-NCAM, TH and the 
dopamine transporter (DAT) was performed to confirm that TH fibers observed close 
to PSA-NCAM interneurons were dopaminergic. Many TH/DAT double-labeled fibers 
and puncta were observed close to PSA-NCAM expressing neurons (figure 19 F & 
G). 
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Figure 19. Confocal microscopic analysis of PSA-NCAM immunoreactive neurons and dopaminergic fibers in the 
mPFC. A: Triple PSA-NCAM/D2R/CB immunohistochemistry in the cingulate cortex layer III. Note the presence of D2R 
expression (arrowhead) in the cytoplasm of the PSA-NCAM/CB expressing somata. B & C: PSA-NCAM immunoreactive 
neuron in the cingulate cortex layer V. Observe TH puncta apposed to the neuronal somata. A detailed view of the squared 
section can be observed in the insert. D & E: Cingulate cortex layer III. Triple PSA-NCAM/TH/SYN immunohistochemistry. 
Note that the TH immunoreactive fiber contacting the PSA-NCAM expressing soma co-expresses synaptophysin (squared 
area in D2-4 & E2-4 and arrowheads in inserted images). F & G: PSA-NCAM immunoreactive neuron in cingulate cortex 
layer III. Observe the colocalization between TH and DAT fibers and the presence of a TH/DAT immunoreactive puncta in 
close apposition to the neuronal somata (squared area in F2-4 & G2-4 and arrowhead in inserted images. C, E and G are 2D 
projections of reconstructions of the focal planes shown in B1-3, D1-4 and F1-4, respectively, and its previous and 
subsequent focal planes located 1 μm apart. Scale bar: 10 μm. PSA-NCAM: polysialylated form of the neural cell adhesion 
molecule; D2R: dopamine D2 receptor; CB: calbindin; TH: tyrosine hydroxylase; SYN: synaptophysin; DAT: dopamine 
transporter. 
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1. THE LESION OF THE DOPAMINE MESOCORTICAL PATHWAY 
DECREASES THE EXPRESSION OF PLASTICITY-RELATED PROTEINS 
1.1. PSA-NCAM expression in the mPFC neuropil decreases after 6-OHDA 
lesion 
6-OHDA injection induced a statistically significant decrease in PSA-NCAM 
expression in the mPFC neuropil, when comparing 6-OHDA-treated hemispheres 
with vehicle-injected (control) hemispheres (p=0.042; figure 20). 
 
This downregulation was also found to be statistically significant (p<0.05) in all 
regions (IL, PrL, Cg1 and Cg2) and layers (I, II, III, V, VI) of the mPFC, with the 
exception of IL layer II, where only a trend toward a decrease in PSA-NCAM 
expression could be observed (figure 21). 
For comparative purposes we also analyzed the expression of PSA-NCAM in 
a subcortical region, the ventral thalamic nucleus, and in a cortical region outside the 
mPFC, the endopiriform nucleus. No statistically significant variations in the optic 
density of PSA-NCAM immunoreactivity could be observed in these regions 
(p=0.4559 and p=0.2361, respectively; figure 22). 
Figure 20. Graph representing the changes in the 
intensity of PSA-NCAM neuropil immunoreactivity in 
the mPFC when comparing 6-OHDA-treated 
hemispheres with contralateral vehicle-treated 
hemispheres (control). Asterisk in 6-OHDA bar indicate 
a statistically significant difference from control 
hemisphere after paired Student’s t-test followed by 
Bonferroni’s correction [p<0.05(*)]. Abbreviations: 6-
OHDA, 6-hydroxydopamine hydrobromide; G.L., grey 
level; IR, immunoreactivity; O.D., optic density. 
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Figure 21. Graphs representing the changes in the intensity of PSA-NCAM neuropil immunoreactivity in the 
infralimbic (A), prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices when comparing 6-
OHDA-treated hemispheres with contralateral vehicle-treated hemispheres (control). Asterisks in 6-OHDA bars 
indicate statistically significant differences from control hemisphere after paired Student’s t-test followed by Bonferroni’s 
correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: 6-OHDA, 6-hydroxydopamine hydrobromide; G.L., grey 
levels; IR, immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
 
Figure 22.  Graph showing no changes in the intensity of 
PSA-NCAM neuropil immunoreactivity in the endopiriform 
(EN) and ventral thalamic nuclei (VTN) after 6-OHDA lesion. 
Comparison between 6-OHDA-treated hemispheres and their 
contralateral vehicle-treated hemispheres. No statistically 
significant differences were found after paired Student’s t-test 
followed by Bonferroni’s correction. Abbreviations: 6-OHDA, 6-
hydroxydopamine hydrobromide; EN, endopiriform nucleus; G.L., 
grey levels; IR, immunoreactivity; O.D., optic density; VTN, 
ventral thalamic nucleus. 
 
 71 Results (II)  
1.2. 6-OHDA lesion decreases SYN neuropil expression in the mPFC  
SYN expression in the mPFC neuropil decreased after dopamine cortical 
depletion (p<0.0001; figure 23). 
 
 
Statistically significant decreases in SYN expression could also be observed in 
all regions (IL, PrL, Cg1 and Cg2) and layers (I, II, III, V, VI) of the mPFC (see figure 
24 for further details).  
Neither the ventral thalamic nucleus nor the endopiriform nucleus showed 
statistically significant variations in the optic density of SYN immunoreactivity 
(p=0.6573 and p=0.5814, respectively; figure 25). 
 
 
Figure 23. Graph showing the changes in the 
intensity of SYN neuropil immunoreactivity in the 
mPFC when comparing 6-OHDA-treated 
hemispheres with contralateral vehicle-treated 
hemispheres (control). Asterisk in 6-OHDA bar indicate 
a statistically significant difference from control 
hemisphere after paired Student’s t-test followed by 
Bonferroni’s correction [p<0.001(***)]. Abbreviations: 6-
OHDA, 6-hydroxydopamine hydrobromide; G.L., grey 
level; IR, immunoreactivity; O.D., optic density. 
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Figure 25.  Graph showing no changes in the intensity of 
SYN neuropil immunoreactivity in the endopiriform (EN) and 
ventral thalamic nuclei (VTN) after 6-OHDA lesion. 
Comparison between 6-OHDA-treated hemispheres and their 
contralateral vehicle-treated hemispheres. No statistically 
significant differences were found after paired Student’s t-test 
followed by Bonferroni’s correction. Abbreviations: 6-OHDA, 6-
hydroxydopamine hydrobromide; EN, endopiriform nucleus; G.L., 
grey levels; IR, immunoreactivity; O.D., optic density; VTN, 
ventral thalamic nucleus. 
 
Figure 24. Graphs representing the changes in the intensity of SYN neuropil immunoreactivity in the infralimbic (A), 
prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices when comparing 6-OHDA-treated 
hemispheres with contralateral vehicle-treated hemispheres (control). Asterisks in 6-OHDA bars indicate statistically 
significant differences from control hemisphere after paired Student’s t-test followed by Bonferroni’s correction; p<0.05 (*), 
p<0.01 (**), p<0.001 (***). Abbreviations: 6-OHDA, 6-hydroxydopamine hydrobromide; G.L., grey levels; IR, 
immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
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1.3. GAD67 expression in the mPFC neuropil decreases after 6-OHDA lesion  
The lesion of the dopamine mesocortical pathway induced a significant 
decrease in GAD67 neuropil expression in the mPFC (p=0.002; figure 26). 
 
This reduction was also statistically significant in all layers of the Cg2; layers I, 
III, V and VI of the IL and PrL; and layers I, III and V of the Cg1 (figure 27). The other 
layers in the four regions of the mPFC did not show statistically significant changes in 
GAD67 neuropil expression, although a clear trend towards a decrease could be 
observed in all of them. 
The optic density of GAD67 immunoreactivity did not show statistically 
significant variations after 6-OHDA lesion neither in the ventral thalamic nucleus nor 
in the endopiriform nucleus (p=0.2327 and p=0.3656, respectively; figure 28). 
 
 
Figure 26. Graph showing the changes in the 
intensity of GAD67 neuropil immunoreactivity in the 
mPFC when comparing 6-OHDA-treated 
hemispheres with contralateral vehicle-treated 
hemispheres (control). Asterisk in 6-OHDA bar indicate 
a statistically significant difference from control 
hemisphere after paired Student’s t-test followed by 
Bonferroni’s correction [p<0.01(**)]. Abbreviations: 6-
OHDA, 6-hydroxydopamine hydrobromide; G.L., grey 
level; IR, immunoreactivity; O.D., optic density. 
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Figure 28.  Graph showing no changes in the intensity of 
GAD67 neuropil immunoreactivity in the endopiriform (EN) 
and ventral thalamic nuclei (VTN) after 6-OHDA lesion. 
Comparison between 6-OHDA-treated hemispheres and their 
contralateral vehicle-treated hemispheres. No statistically 
significant differences were found after paired Student’s t-test 
followed by Bonferroni’s correction. Abbreviations: 6-OHDA, 6-
hydroxydopamine hydrobromide; EN, endopiriform nucleus; G.L., 
grey levels; IR, immunoreactivity; O.D., optic density; VTN, 
ventral thalamic nucleus. 
 
Figure 27. Graphs representing the changes in the intensity of GAD67 neuropil immunoreactivity in the infralimbic 
(A), prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices when comparing 6-OHDA-
treated hemispheres with contralateral vehicle-treated hemispheres (control). Asterisks in 6-OHDA bars indicate 
statistically significant differences from control hemisphere after paired Student’s t-test followed by Bonferroni’s correction; 
p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: 6-OHDA, 6-hydroxydopamine hydrobromide; G.L., grey levels; IR, 
immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
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2. HALOPERIDOL, A DOPAMINE D2R ANTAGONIST, DECREASES THE 
EXPRESSION OF PLASTICITY-RELATED PROTEINS IN THE ADULT mPFC. 
2.1. Body weight gain is not affected by haloperidol 
Body weight was measured before the onset of the treatment (day 0), after 13 
days of i.p injections and at the end of the treatment (day 26). All animals increased 
their body weight during the experiment but no statistically significant differences on 
body weight gain could be observed between groups in any of the time-periods 
analyzed (from day 0 to 26th day: p=0.8654; from day 0 to 13th day: p=0.4485; from 
13th to 26th day: p=0.1584). 
2.2. PSA-NCAM expression in the mPFC neuropil decreases after haloperidol 
treatment 
Twenty-six days of haloperidol treatment induced a statistically significant 
decrease in PSA-NCAM neuropil expression in the rat mPFC (p<0.0001; figure 29), 
that could also observed in layers I and III of the IL, and layers I, III and V of the PrL, 
Cg1 and Cg2. A trend towards a decrease could be observed in PSA-NCAM 
expression in the remaining layers (figure 30). 
 
Haloperidol treatment also induced a statistically significant decrease in PSA-
NCAM expression in the ventral thalamic nucleus (p=0.0331) but no significant 
variations were detected in the endopiriform nucleus (p=0.2606; figure 31). 
Figure 29. Graph showing the changes in the 
intensity of PSA-NCAM neuropil immunoreactivity in 
the mPFC after chronic haloperidol treatment. 
Asterisks in haloperidol bar indicate a statistically 
significant difference from control group after univariate 
repeated measures ANOVA [p<0.001(***)] followed by 
Bonferroni’s correction. Abbreviations: G.L., grey level; 
HALOPER, haloperidol; IR, immunoreactivity; O.D., optic 
density. 
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Figure 30. Graphs showing the changes in the intensity of PSA-NCAM neuropil immunoreactivity in the infralimbic 
(A), prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after chronic haloperidol 
treatment. Asterisks in bars indicate statistically significant differences between groups after univariate repeated measures 
ANOVA followed by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). 
Abbreviations: G.L., grey levels; IR, immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
 
Figure 31.  Graph showing changes in the intensity of PSA-
NCAM neuropil immunoreactivity in the endopiriform (EN) 
and ventral thalamic nuclei (VTN) after chronic haloperidol 
treatment. Asterisks in bars indicate statistically significant 
differences between groups after unpaired Student’s t-test 
followed by Bonferroni’s correction [p<0.05 (*)]. Abbreviations: 
EN, endopiriform nucleus; G.L., grey levels; IR, immunoreactivity; 
O.D., optic density; VTN, ventral thalamic nucleus. 
 
 77 Results (II)  
2.3. SYN neuropil expression decreases after haloperidol treatment in the 
mPFC 
A statistically significant decrease in SYN expression could be observed after 
pharmacological treatment with haloperidol in the mPFC neuropil (p<0.0001; figure 
32). Several layers of the IL, PrL, Cg1 and Cg2 also showed statistically significant 
decreases in SYN neuropil immunoreactivity (see figure 33 for further details). 
 
Neither the ventral thalamic nucleus (p=0.2089) nor the endopiriform nucleus 
(p=0.4701) showed significant variations in the optic density of SYN immunoreactivity 
(figure 34). 
Figure 32. Graph showing the changes in the 
intensity of SYN neuropil immunoreactivity in the 
mPFC after chronic haloperidol treatment. Asterisks 
in haloperidol bar indicate a statistically significant 
difference from control group after univariate repeated 
measures ANOVA [p<0.001(***)] followed by 
Bonferroni’s correction. Abbreviations: G.L., grey level; 
HALOPER, haloperidol; IR, immunoreactivity; O.D., optic 
density. 
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Figure 33. Graphs showing the changes in the intensity of SYN neuropil immunoreactivity in the infralimbic (A), 
prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after chronic haloperidol treatment. 
Asterisks in bars indicate statistically significant differences between groups after univariate repeated measures ANOVA 
followed by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: 
G.L., grey levels; IR, immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
 
Figure 34.  Graph showing changes in the intensity of SYN 
neuropil immunoreactivity in the endopiriform (EN) and 
ventral thalamic nuclei (VTN) after chronic haloperidol 
treatment. No statistically significant differences between groups 
were found after unpaired Student’s t-test followed by 
Bonferroni’s correction. Abbreviations: EN, endopiriform nucleus; 
G.L., grey levels; IR, immunoreactivity; O.D., optic density; VTN, 
ventral thalamic nucleus. 
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2.4. GAD67 expression in the mPFC decreases after haloperidol treatment 
A significant decrease in GAD67 expression could be observed after 
haloperidol treatment in the mPFC neuropil (p<0.0001; figure 35), that is also 
statistically significant in many layers of IL, PrL, Cg1 and Cg2 (see figure 36). 
 
GAD67 neuropil expression did not show statistically significant variations after 
haloperidol treatment neither in the ventral thalamic nucleus (p=0.9407) nor in the 
endopiriform nucleus (p=0.3403) (figure 37). 
Figure 35. Graph showing the changes in the 
intensity of GAD67 neuropil immunoreactivity in the 
mPFC after chronic haloperidol treatment. Asterisks 
in haloperidol bar indicate a statistically significant 
difference from control group after univariate repeated 
measures ANOVA [p<0.001(***)] followed by 
Bonferroni’s correction. Abbreviations: G.L., grey level; 
HALOPER, haloperidol; IR, immunoreactivity; O.D., optic 
density. 
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Figure 36. Graphs showing the changes in the intensity of GAD67 neuropil immunoreactivity in the infralimbic (A), 
prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after chronic haloperidol treatment. 
Asterisks in bars indicate statistically significant differences between groups after univariate repeated measures ANOVA 
followed by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: 
G.L., grey levels; IR, immunoreactivity; O.D., optic density. Roman numbers indicate cortical layers. 
 
Figure 37.  Graph showing changes in the intensity of GAD67 
neuropil immunoreactivity in the endopiriform (EN) and 
ventral thalamic nuclei (VTN) after chronic haloperidol 
treatment. No statistically significant differences between groups 
were found after unpaired Student’s t-test followed by 
Bonferroni’s correction. Abbreviations: EN, endopiriform nucleus; 
G.L., grey levels; IR, immunoreactivity; O.D., optic density; VTN, 
ventral thalamic nucleus. 
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3. PPHT, A DOPAMINE D2R AGONIST, INCREASES THE EXPRESSION OF 
PLASTICITY-RELATED PROTEINS IN THE ADULT mPFC. 
3.1. PPHT induces a decrease on body weight gain 
Animals were weighted at the beginning (day 0), in the middle (day 4) and at 
the end (day 7) of pharmacological treatment. Body weight gain in animals treated 
with PPHT was significantly lower than in control animals in all the time-periods 
analyzed (from day 0 to 7th day: p=0.0004; from day 0 to 4th day: p=0.0105; from 4th 
to 7th day: p=0.0349). 
3.2. PSA-NCAM expression in the mPFC neuropil increases after PPHT 
treatment 
After seven days of PPHT treatment, significant increases in PSA-NCAM 
neuropil expression could be observed in the mPFC (p<0.0001; figure 38). This 
upregulation was statistically significant in all layers (I, II, III, V and VI) within all 
regions (IL, PrL, Cg1 and Cg2) of the mPFC (figure 39). 
 
PPHT treatment also induced a significant increase in PSA-NCAM neuropil 
expression in the ventral thalamic nucleus (p=0.0114). By contrast, no significant 
variations (p=0.7343) were detected in the endopiriform nucleus (figure 40). 
Figure 38. Graph showing the changes in the 
intensity of PSA-NCAM neuropil immunoreactivity in 
the mPFC after PPHT treatment. Asterisks in 
haloperidol bar indicate a statistically significant 
difference from control group after univariate repeated 
measures ANOVA [p<0.001(***)] followed by 
Bonferroni’s correction. Abbreviations: G.L., grey level; 
IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-
Phenethyl-N-propyl)-amino-5-hydroxytetralin 
hydrochloride. 
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Figure 39. Graphs showing the changes in the intensity of PSA-NCAM neuropil immunoreactivity in the infralimbic 
(A), prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after PPHT treatment. Asterisks in 
bars indicate statistically significant differences between groups after univariate repeated measures ANOVA followed by 
multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: G.L., grey 
levels; IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride. 
Roman numbers indicate cortical layers. 
 
Figure 40.  Graph showing changes in the intensity of PSA-
NCAM neuropil immunoreactivity in the endopiriform (EN) 
and ventral thalamic nuclei (VTN) after PPHT treatment. 
Asterisks in bars indicate statistically significant differences 
between groups after unpaired Student’s t-test followed by 
Bonferroni’s correction [p<0.05 (*)]. Abbreviations: EN, 
endopiriform nucleus; G.L., grey levels; IR, immunoreactivity; 
O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-
hydroxytetralin hydrochloride; VTN, ventral thalamic nucleus. 
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3.3. SYN neuropil expression in the mPFC increases after PPHT treatment 
PPHT treatment induced statistically significant increases in SYN expression 
in the mPFC neuropil (p<0.0001; figure 41). With the exception of layer II in the 
ventral and dorsal cingulate cortices, all layers in all regions of the mPFC showed 
statistically significant increases in SYN neuropil expression (figure 42). 
 
Neither the ventral thalamic nucleus (p=0.8341) nor the endopiriform nucleus 
(p=0.3948) showed significant variations in the optic density of SYN immunoreactivity 
(figure 43). 
Figure 41. Graph showing the changes in the 
intensity of SYN neuropil immunoreactivity in the 
mPFC after PPHT treatment. Asterisks in haloperidol 
bar indicate a statistically significant difference from 
control group after univariate repeated measures 
ANOVA [p<0.001(***)] followed by Bonferroni’s 
correction. Abbreviations: G.L., grey level; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-
Phenethyl-N-propyl)-amino-5-hydroxytetralin 
hydrochloride. 
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Figure 42. Graphs showing the changes in the intensity of SYN neuropil immunoreactivity in the infralimbic (A), 
prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after PPHT treatment. Asterisks in bars 
indicate statistically significant differences between groups after univariate repeated measures ANOVA followed by multiple 
pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: G.L., grey levels; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride. Roman 
numbers indicate cortical layers. 
 
Figure 43.  Graph showing changes in the intensity of SYN 
neuropil immunoreactivity in the endopiriform (EN) and 
ventral thalamic nuclei (VTN) after PPHT treatment. No 
statistically significant differences between groups were found 
after unpaired Student’s t-test followed by Bonferroni’s correction. 
Abbreviations: EN, endopiriform nucleus; G.L., grey levels; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-
propyl)-amino-5-hydroxytetralin hydrochloride; VTN, ventral 
thalamic nucleus. 
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3.4. PPHT treatment increases GAD67 neuropil expression in mPFC  
Statistically significant increases in GAD67 neuropil expression in the mPFC 
could be observed after PPHT treatment (p<0.0001; figure 44). This significant 
upregulation could be observed in most layers of all regions (IL, PrL, Cg1 and Cg2) in 
the mPFC (see figure 45 for further details). 
 
The optic density of GAD67 immunoreactivity did not show statistically 
significant variations after PPHT treatment neither in the ventral thalamic nucleus 
(p=0.3720) nor in the endopiriform nucleus (p= 0.2743) (figure 46). 
Figure 44. Graph showing the changes in the 
intensity of GAD67 neuropil immunoreactivity in the 
mPFC after PPHT treatment. Asterisks in haloperidol 
bar indicate a statistically significant difference from 
control group after univariate repeated measures 
ANOVA [p<0.001(***)] followed by Bonferroni’s 
correction. Abbreviations: G.L., grey level; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-
Phenethyl-N-propyl)-amino-5-hydroxytetralin 
hydrochloride. 
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Figure 45. Graphs showing the changes in the intensity of GAD67 neuropil immunoreactivity in the infralimbic (A), 
prelimbic (B), dorsal cingulate (C; Cg1) and ventral cingulate (D; Cg2) cortices after PPHT treatment. Asterisks in bars 
indicate statistically significant differences between groups after univariate repeated measures ANOVA followed by multiple 
pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***). Abbreviations: G.L., grey levels; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride. Roman 
numbers indicate cortical layers. 
 
Figure 46.  Graph showing changes in the intensity of GAD67 
neuropil immunoreactivity in the endopiriform (EN) and 
ventral thalamic nuclei (VTN) after PPHT treatment. No 
statistically significant differences between groups were found 
after unpaired Student’s t-test followed by Bonferroni’s correction. 
Abbreviations: EN, endopiriform nucleus; G.L., grey levels; IR, 
immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-
propyl)-amino-5-hydroxytetralin hydrochloride; VTN, ventral 
thalamic nucleus. 
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4. TEMPORAL DIFFERENCES IN THE EXPRESSION OF PLASTICITY-RELATED 
GENES DURING PPHT TREATMENT IN THE mPFC 
4.1. Body weight decreases after acute or chronic PPHT treatment 
At the end of the experiment, all PPHT-treated groups showed statistically 
significant decreases in their body weights when compared with their respective 
control group (1 day-treatment group: p=0.0026; 4 days-treatment group: p=0.0005; 
7 days-treatment group: p=0.0030). In particular, these decreases took place during 
the first half of the treatment (from day 0 to 2nd day in the 4 days-treatment group: 
p=0.0018; from day 0 to 4th day in the 7 days-treatment group: p=0.0009). After that, 
PPHT-treated animals increased their body weight similar to controls (from 2nd to 4th 
day in the 4 days-treatment-group: p=0.2668; from 4th to 7th day in the 7 days-
treatment group: p=0.2442). 
4.2. Time-course changes in mPFC gene expression during PPHT treatment 
4.2.1. Expression of polysialyltransferase genes st8siaII and st8siaIV 
After 1 day of PPHT treatment, st8siaII and st8siaIV mRNA levels in the mPFC 
did not significantly differ from those of the control group (figure 47 A). Four days of 
treatment significantly increased st8siaIV gene expression (p=0.047; fold 
increase=1.26) but did not change st8siaII mRNA levels (figure 47 B). At the end of 
the experiment (7th day), the expression of both polysialyltransferase genes did not 
show statistically significant differences when compared with that of the control group 
(figure 47 C) (table 4). 
Table 4. qRT-PCR results in the mPFC of PPHT-treated rats vs. control 
 
 1 day  4 days  7days 
∆ p-value  ∆ p-value  ∆ p-value 
 
ncam 
syn 
gad67 
gad65 
st8siaII 
st8siaIV 
 
 
0.8950 
0.8846 
1.0179 
1.1526 
0.9024 
0.9655 
   
   0.6257  
   0.6587  
   0.9178  
   0.4574  
   0.7450  
   0.8820  
 
  
0.9264 
1.0981 
1.3210 
1.4093 
1.3486 
1.2622 
    
   0.4911  
   0.5942  
   0.0492  
   0.0418  
   0.1943  
   0.0470  
 
  
0.5020 
0.8751 
0.5090 
1.3675 
1.3784 
1.9053 
     
    0.0002  
    0.7912  
    0.1601  
    0.3327  
    0.4832  
    0.1240  
 
 
∆, fold change in mRNA levels in PPHT-treated animals relative to control animals. Information in bold represents significant 
changes (p<0.05) after unpaired Student’s t-test followed by Bonferroni’s correction. 
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4.2.2. Ncam gene expression 
No statistically significant changes were found in ncam gene expression after 
1 or 4 days of PPHT treatment but a significant 0.5-fold decrease in ncam mRNA 
level was observed after 7 days of treatment (p=0.0002) (figure 47) (table 4). 
4.2.3. Syn gene expression 
No statistically significant changes were found in syn gene expression after 1, 
4 or 7 days of PPHT treatment (figure 47) (table 4). 
4.2.4. Expression of glutamate decarboxylase genes gad65 and gad67 
Both gad65 and gad67 genes only were found to increase their expression 
after 4 days of PPHT treatment (gad65: p=0.0418, fold increase=1.4; gad67: 
p=0.0492, fold increase=1.3). The expression of both genes did not change after 1 or 
7 days of treatment (figure 47) (table 4). 
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Figure 47. Time-course changes of 
ncam, syn, gad65, gad67, siaII and 
sia IV gene expression after 1 day 
(A), 4 days (B) and 7 days (C) of 
PPHT treatment in the mPFC of adult 
rats. Bars indicate fold change values 
on mRNA level when compare the 
treated and the control group in each 
time point. Asterisks in bars indicate 
statistically significant differences from 
the control group in unpaired Student’s 
t-test followed by Bonferroni correction: 
p<0.05 (*), p< 0.01(***), p<0.001(***). 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
C 
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Effects of PSA depletion on the 
remodeling of inhibitory networks and 
pyramidal neurons in the mPFC and its 
influence on the neuroplastic changes 
mediated by D2R agonists 
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1. DOPAMINE D2 RECEPTORS AND POLYSIALIC ACID PARTICIPATE IN 
THE REMODELING OF INHIBITORY NETWORKS AND PYRAMIDAL 
NEURONS IN THE mPFC 
1.1. Body weight loss after PPHT treatment 
 From the day of surgery (day 0) to the onset of pharmacological treatment 
(day 7), no statistically significant differences were found on body weight between 
groups (p=0.087). After PPHT treatment (from 7th to 14th day), animals showed a 
significant weight loss when compared with non-PPHT treated ones (Endo-N/PPHT 
vs. Endo-N/Control: p<0.0001; Control/PPHT vs. Control/Control: p=0.0246). These 
decreases on body weight took place specifically from 7th to 10th day (EndoN/PPHT 
vs. Endo-N/Control: p<0.0001; Control/PPHT vs. Control/Control: p=0.005); from day 
10th to 14th, all groups increased equally their body weight (p=0.322). 
 
All the results that will be shown in the following sections (from 1.2 to 1.6) are 
summarized in table 5. 
1.2. Endo-N injection blocks PPHT-induced increases in SYN and GAD67 
expression in the mPFC neuropil, and reduces VGLUT1 expression 
In consonance with our previous results (see chapter 5, section 3.2-3.4), 
seven days of PPHT treatment induced statistically significant increases in PSA-
NCAM (p<0.001), SYN (p=0.003) and GAD67 (p<0.001) expression in the mPFC 
neuropil. These effects of PPHT on SYN and GAD67 expression were prevented 
when PSA was removed one week before the onset of the PPHT treatment 
[Control/Control vs. Endo-N/PPHT: p=1.000 (SYN), p=0.139 (GAD67); Endo-
N/Control vs. Endo-N/PPHT: p=1.000 (SYN and GAD67)] (figure 48 A-C). PSA-
NCAM expression in the mPFC remained undetectable 14 days after Endo-N 
injection (figure 49). 
VGLUT1 expression in the neuropil was not affected by PPHT treatment, 
neither in the presence nor in the absence of PSA (Control/Control vs. Control/PPHT 
or Endo-N/Control vs. Endo-N/PPHT: p=1.000) (figure 48 D). 
Endo-N administration by itself did not induce changes in GAD67 or SYN 
expression, but decreased VGLUT1 expression in the mPFC neuropil [Endo-
 94 Chapter 6 
N/Control vs. Control/Control: p=1.000 for GAD67 and SYN, p=0.028 for VGLUT1) 
(figure 48 B-D).  
 
 
 
Figure 48. Graphs showing changes in the expression of PSA-NCAM (A),  SYN (B), GAD67 (C) and VGLUT1 (D)  in 
the mPFC neuropil after Endo-N or PPHT treatments and their combination. Asterisks in bars indicate statistically 
significant differences between groups (see graph legend) after univariate repeated measures ANOVA followed by multiple 
pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***).Abbreviations: Endo-N, Endo-N-
acetylneuraminidase; G.L., grey levels; IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-
hydroxytetralin hydrochloride. 
 
Figure 49. Microphotographs showing PSA-NCAM immunostaining in control (A) and Endo-N treated rats (B). Note 
in panel B the lack of PSA-NCAM expression in the cingulate cortex, but not in the striatum. Scale bar: 100 μm. 
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The effects described above for PSA-NCAM, SYN, GAD67 and VGLUT1 
expression, considering the whole mPFC neuropil, were also observed in most layers 
of every region within the mPFC (IL, PrL, Cg1 and Cg2) (figure 50-53).  
 
 
 
Figure 50. Graphs representing the changes in PSA-NCAM neuropil expression after Endo-N and/or PPHT 
treatments. (A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in 
bars indicate statistically significant differences between groups (see graph legend) after univariate repeated measures 
ANOVA followed by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 
(***).Abbreviations: Endo-N, Endo-N-acetylneuraminidase; G.L., grey levels; IR, immunoreactivity; O.D., optic density; 
PPHT, 2-(N-Phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride. Roman numbers indicate cortical layers. 
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Figure 51. Graphs showing the changes in SYN neuropil expression after Endo-N and/or PPHT treatments. (A) 
Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in bars indicate 
statistically significant differences between groups (see graph legend) after univariate repeated measures ANOVA followed 
by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***).Abbreviations: Endo-N, 
Endo-N-acetylneuraminidase; G.L., grey levels; IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-
amino-5-hydroxytetralin hydrochloride. Roman numbers indicate cortical layers. 
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Figure 52. Graphs showing the changes in GAD67 neuropil expression after Endo-N and/or PPHT treatments. (A) 
Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in bars indicate 
statistically significant differences between groups (see graph legend) after univariate repeated measures ANOVA followed 
by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***).Abbreviations: Endo-N, 
Endo-N-acetylneuraminidase; G.L., grey levels; IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-propyl)-
amino-5-hydroxytetralin hydrochloride. Roman numbers indicate cortical layers. 
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Figure 53. Graphs representing the changes in VGLUT1 neuropil expression after Endo-N and/or PPHT treatments. 
(A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in bars 
indicate statistically significant differences between groups (see graph legend) after univariate repeated measures ANOVA 
followed by multiple pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***).Abbreviations: 
Endo-N, Endo-N-acetylneuraminidase; G.L., grey levels; IR, immunoreactivity; O.D., optic density; PPHT, 2-(N-Phenethyl-N-
propyl)-amino-5-hydroxytetralin hydrochloride. Roman numbers indicate cortical layers. 
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1.3. PPHT treatment increases the number of PSA-NCAM expressing 
interneurons in the mPFC, without affecting their phenotype. 
In consonance with the observed increase in PSA-NCAM expression in the 
neuropil after PPHT treatment, the number of PSA-NCAM expressing interneurons in 
the mPFC was also higher in PPHT-treated animals than in non-treated ones 
(p=0.0004) (figure 54 A & C). In particular, statistically significant differences were 
observed in layers III, V and VI of infralimbic, prelimbic, dorsal cingulate and ventral 
cingulate cortices (figure 55). 
 Nevertheless, the percentages of PSA-NCAM expressing interneuron somata 
belonging to different interneuron subpopulations (defined by calcium-binding protein 
expression) did not change after PPHT treatment (p>0.05 in all comparisons; figure 
54 B). Most PSA-NCAM interneurons co-expressed CB (74.0 ± 2.6% in control 
group, 75.3 ± 4.7% in PPHT treated group; figure 54 B & D), but much lower 
percentages co-expressed CR (3.7 ± 0.8% in control group, 4.5 ± 1.7% in PPHT 
treated group; figure 54 B & E) or PV (1.7 ± 0.8% in control group, 1.0 ± 0.6 % in 
PPHT treated group; figure 54 B & F). 
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Figure 54. Quantification and confocal microscopic analysis of the neurochemical phenotype of PSA-NCAM 
expressing interneurons in mPFC after PPHT treatment. (A) Graph showing statistically significant differences in the 
number of PSA-NCAM expressing somata from control group after unpaired Student’s t-test followed by Bonferroni’s 
correction; p<0.001 (). (B) Graph representing the percentages of PSA-NCAM expressing interneuron somata belonging 
to different interneuron subpopulations (defined by calcium-binding protein expression). No statistically significant 
differences from control group were observed after unpaired Student’s t-tests followed by Bonferroni’s correction (p>0.05 in 
all comparisons). (C) Multipolar neuron expressing PSA-NCAM in dorsal Cingulate Cortex (Cg1) layer V observed by 
conventional light microscopy. (D) PSA-NCAM interneuron in Cg1 layer V co-expressing CB. (E) PSA-NCAM / CR double 
labeled interneuron in ventral Cingulate Cortex (Cg2) layer V. (F) Lack of co-localization between PSA-NCAM (F1) and PV 
(F2) expressing neurons in Cg1 layer III. D-F images are 2D projections of focal planes located 1 µm apart. Scale bar: 10 
µm. Insets in the images are 2X enlarged views taken from single confocal planes of the areas marked with arrowheads. 
 101 Results (III)  
 
 
Figure 55. Graphs showing the changes in the number of PSA-NCAM immunoreactive neurons after PPHT 
treatment. (A) Infralimbic cortex; (B) Prelimbic cortex; (C) Dorsal cingulate cortex; (D) Ventral cingulate cortex. Asterisks in 
bars indicate statistically significant differences from control group after repeated measures ANOVA followed by multiple 
pair-wise comparisons with Bonferroni’s correction; p<0.05 (*), p<0.01 (**), p<0.001 (***).Abbreviations: PPHT, 2-(N-
Phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride. Roman numbers indicate cortical layers. 
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1.4. Effects of PPHT and Endo-N treatments on perisomatic puncta on 
mPFC pyramidal neurons 
1.4.1. PPHT treatment increases the density of PSA-NCAM expressing 
perisomatic puncta 
PPHT treatment induces a statistically significant 123.8% increase in the 
density of PSA-NCAM expressing puncta surrounding pyramidal neuron somata 
(p=0.0023; figure 56 A), which is in line with the effects described above in PSA-
NCAM expressing neuropil and interneurons (section 1.2 and 1.3).  
1.4.2. PPHT and/or Endo-N treatments increase the density of inhibitory 
perisomatic puncta 
Both PPHT and Endo-N treatments when administered by themselves induced 
statistically significant increases (p<0.0001 in all cases) in the density of GAD65/67 
(33.2% and 82.54%, respectively; figure 56 B) and PV (19.2% and 38.59%, 
respectively figure 56 C) expressing puncta in the perisomatic region of pyramidal 
neurons. However, the combination of both treatments induced statistically significant 
but lower increases than those observed after Endo-N treatment alone (45.8% 
increase, p<0.0001 for GAD65/67; 23.8% increase, p<0.0001 for PV; figure 56 B & 
C). 
1.4.3. Endo-N, by itself or administered before PPHT treatment, increases the 
density of SYN perisomatic puncta 
Endo-N administration by itself, induced a statistically significant 30.5% 
increase in the density of SYN expressing puncta surrounding pyramidal neuron 
somata (p<0.0001). Increases were even higher when PPHT was administered after 
Endo-N injection (44.7% increase; p<0.0001 compared with Control/Control; 
p=0.0008 compared with Endo-N/Control). By contrast, PPHT treatment alone did not 
change the density of SYN perisomatic puncta (p=0.6660) (figure 56 D). 
1.4.4. PPHT decreases and Endo-N increases the percentage of PV perisomatic 
puncta co-expressing SYN 
After PPHT treatment, 21.20 ± 0.53 %  of PV expressing puncta surrounding 
pyramidal neuron somata were found to co-express SYN, which implied a small but 
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significant decrease of this percentage (p<0.0001) when compared with that of the 
control group (32.82 ± 0.56 %). Conversely, Endo-N administration induced a 
statistically significant increase of this percentage, reaching 48.16 ± 0.99 % 
(p<0.0001). When Endo-N was administered before PPHT treatment, 44.72 ± 0.65 % 
of PV puncta co-expressed SYN, a percentage significantly lower than that of Endo-
N/Control group (p=0.0006) but still higher than that of the Control/Control group 
(p<0.0001) (figure 56 E). 
 
 
Figure 56. Graphs representing the changes in the density of PSA-NCAM, GAD67, PV and SYN expressing puncta 
in mPFC pyramidal neurons after Endo-N or PPHT treatments and their combination. (A-D) Perisomatic density of 
PSA-NCAM (A), GAD67 (B), PV (C) and SYN (D) expressing puncta, measured as the number of puncta/ μm of the 
pyramidal cell soma perimeter. (E) Percentage of PV expressing puncta co-expressing SYN. (F) Peridendritic density of 
GAD67 expressing puncta measured as number of puncta/ μm of the apical dendrite length. Asterisks in bars indicate 
statistically significant differences between groups (see graph legend) after one-way ANOVA followed by Bonferroni’s 
correction; p<0.05 (), p<0.01 (), p<0.001 (). 
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1.5. Endo-N blocks PPHT-induced increases in GAD65/67 puncta density 
on the apical dendrites of mPFC pyramidal neurons 
Similar to that described above for GAD67 expression in mPFC neuropil 
(section 1.2), PPHT treatment induced a significant increase (15.6%) in the density of 
peridendritic puncta expressing GAD65/67 (Control/Control vs. Control/PPHT: 
p=0.0215), which was blocked when animals were previously treated with Endo-N 
(Endo-N/Control vs. Endo-N/PPHT: p=0.5877). Endo-N administration by itself, did 
not change GAD65/67 peridendritic puncta density (p=0.2712) (figure 56 F). 
1.6. PPHT and EndoN by themselves or in combination decrease dendritic 
spine density in mPFC pyramidal neurons  
PPHT treatment induced a statistically significant overall decrease in dendritic 
spine density (Control/Control vs. Control/PPHT: p<0.0001; 20.7% decrease) (figure 
57 A). Considering the distance from the soma, decreases in the spine density were 
only statistically significant from the second 50 μm-length segment onwards (first 
segment: p=0.4176; the rest of segments: p<0.0001) (figure 57 B). 
When PSA was removed before PPHT treatment, the decrease in dendritic 
spine density was higher (37.9%) (Endo-N/PPHT vs. Control/Control: p<0.0001) 
(figure 57 A). Decreases were statistically significant from the second to the fourth 
50 μm-length segment (p<0.0001 in all cases) (figure 57 B). 
PSA depletion by itself also produced an overall 44.5 % decrease in spine 
density throughout the apical dendrites (200 μm-length) of mPFC pyramidal neurons 
(Control/Control vs. Endo-N/Control: p<0.0001) (figure 57 A). Statistically significant 
decreases in spine density were also found in all the four 50 μm-length segments in 
which the apical dendrites were divided (p<0.0001 in all cases) (figure 57 B). 
When EndoN/PPHT group was compared with Endo-N/Control group, a 
statistically significant 10.5 % increase in the spine density throughout apical 
dendrites was detected (p=0.0058) (figure 57 B).  
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Figure 57. Dendritic spine density in mPFC pyramidal neurons is decreased after PPHT or Endo-N treatment and 
their combination. (A) Graph showing statistically significant differences between groups (see figure legend) when 
consider the total length (200 µm) of the measured dendrites. (B) Camera lucida drawings of 50 µm-length dendritic 
segments located 150-200 µm distal from the soma in dorsal cingulate cortex (Cg1), layer III. Note the decreased number of 
dendritic spines in all treated groups when compare with control/control group. (C) Graph representing dendritic spine 
density as function of distance from the soma in 50 µm-length segments. Asterisks in bars indicate statistically significant 
differences between groups (see graph legend) after one-way ANOVA followed by Bonferroni’s correction. For graph (A): 
p<0.05 (), p<0.01 (), p<0.001 (). For graph (B), please see p-values in the results section. For graph (C), please see 
p-values in the results section. Abbreviations: Endo-N, Endo-N-acetylneuraminidase; PPHT, 2-(N-Phenethyl-N-propyl) 
amino-5-hydroxytetralin hydrochloride. 
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Table 5. Summary of results: differences from Control/Control group   
 CONTROL ENDO-N ENDO-N 
 PPHT CONTROL PPHT 
Neuropil protein expression    
PSA-NCAM  ***   
SYN  ** = = 
GAD67  *** = = 
VGLUT1 =  *  ** 
    
PSA-NCAM expressing neurons    
Number of neurons  ***   
% of co-localization with CB =   
% of co-localization with CR =   
% of co-localization with PV =   
    
Perisomatic puncta on pyramidal neurons    
δ PSA-NCAM  **   
δ GAD65/67  ***  ***  *** 
δ PV  ***  ***  *** 
δ SYN =  ***  *** 
% of PV puncta co-expressing SYN  ***  ***  *** 
    
Apical dendrite of pyramidal neurons    
δ GAD65/67 peridendritic puncta  * = = 
δ spines  ***  ***  *** 
    
    
No statistically significant differences (=) or statistically significant increases () or decreases () on the parameters measured, 
when compared with control/control group following the appropriate statistical analysis (see materials and methods section); 
p<0.05 (*), p<0.01 (**), p<0.001 (***).  
Abbreviations: δ, density (number of puncta or spines/µm of soma perimeter or dendrite length); PSA-NCAM, polysialylated 
form of de neural cell adhesion molecule; SYN, synaptophysin; GAD67, 67 kDa isoform of the glutamate decarboxilase 
enzime, GAD65/67, both 65 and 67 kDa isoforms of the glutamate decarboxilase enzyme; VGLUT1, vesicular glutamate 
transporter 1; CB,  calbindin-D28k;  CR , calretinin;  PV, parvalbumin. 
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2. SHORT-TERM PSA DEPLETION IN VITRO INDUCES STRUCTURAL 
CHANGES IN INTERNEURONS AND AFFECTS THE CONECTIVITY OF 
PYRAMIDAL NEURONS 
2.1. Microscopic architecture of mPFC and PSA-NCAM expression in 
organotypic cultures  
After 14 days in vitro, mPFC conserved their appearance (figure 58 A) and 
microscopic architecture (figure 58 A & B) as it was in vivo. PSA-NCAM expression 
was observed in neurons and neuropil in the vehicle-treated slices (control; figure 58 
D1) but it was completely absent in Endo-N treated slices (figure 58 D2). 
 
 
2.2. Endo-N decreases dendritic spine density in GAD-GFP expressing 
interneurons of mPFC organotypic cultures 
Two days after the Endo-N delivery, GAD-GFP expressing interneurons 
showed a 28.1% decrease (p=0.0485) in dendritic spine density on the third 60 µm-
length segment in which the dendrites were divided (120-180 µm distance from the 
soma). No statistically significant differences in spine density were found when we 
Figure 58. Photographs showing the microscopic architecture of mPFC and PSA-NCAM expression in organotypic 
cultures. (A)Panoramic view of mPFC slice after 14 days in vitro before being fixed. (B-C) Microphotographs showing that 
the layered organization of neurons in the mPFC is conserved after 14 days in vitro. (B) Nissl stained slice. (C) Slice 
processed for NeuN immunohistochemistry. (C) PSA-NCAM expression is observed in neurons and neuropil in the vehicle-
treated slices (control; D1) but it is completely absent in Endo-N treated-slices (D2). Scale bar: 25 μm (B-C), 100 μm (D1-
D2) 
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analyzed the other segments or the overall dendrite length, but a trend towards a 
decrease could be observed in all these cases (figure 59). 
 
 
2.3. Effects of Endo-N treatment on the perisomatic puncta of mPFC 
pyramidal neurons 
2.3.1. Endo-N increases the density of inhibitory perisomatic puncta 
In consonance with the effects observed in vivo after long-term PSA depletion 
(section 1.4.1), short-term Endo-N delivery in vitro also induced statistically significant 
increases in the density of inhibitory puncta surrounding the somata of pyramidal 
neurons (δGAD-GFP: p<0.0001; δVGAT: p=0.0007; δPV: p=0.0002) (figure 60 A).  
2.3.2. Endo-N increases the density of excitatory perisomatic puncta 
The density of VGLUT1 expressing puncta in the perisomatic region of 
pyramidal neurons increased 2 days before the delivery of Endo-N in mPFC 
organotypic cultures (p<0.0001) (figure 60 A).  
2.3.3. Endo-N increases the density of SYN perisomatic puncta 
Short term PSA depletion induced a statistically significant increase in the 
density of SYN puncta surrounding the somata of pyramidal neurons (p<0.0001), 
Figure 59. Confocal microscopic analysis of dendritic spine density in GAD-GFP expressing interneurons of mPFC 
organotypic cultures. (A)Graphs comparing dendritic spine density of GAD-GFP expressing interneurons from mPFC 
slices treated with Endo-N with those from slices treated with vehicle solution (control). 60, 120 and 180 indicate dendrite 
segments of 60 µm located from 0 to 60, 60 to 120 and 120 to 180 µm from the soma interneuron, respectively. Asterisk in 
bars indicate statistically significant differences in unpaired Student t-test: p<0.05 (*), p<0.01 (**), p<0.001. (B1-B2) 
Confocal microscopic images of GAD-GFP expressing interneurons in mPFC organotypic cultures treated with vehicle 
solution (control; B1) or Endo-N (B2). Note the decreased number of dendritic spines after Endo-N treatment. Insets in the 
images are 3X enlargements of squared areas. Scale bar: 250 μm 
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similar to what we observed in vivo after long-term PSA depletion (section 1.4.2) 
(figure 60 A). 
2.3.4. Changes in neuropil protein expression after Endo-N treatment 
Endo-N induced a statistically significant decrease in VGAT neuropil expression 
(p=0.0382) and statistically significant increases in VGLUT1 and CB puncta 
(p<0.0001 in both cases). No statistically significant differences where found when 
analyzed GAD-GFP or SYN neuropil expression, in consonance with long-term PSA 
depletion results (figure 60 B). 
 
 
Figure 60. Graphs representing the changes in the density of GAD-GFP, VGAT, PV, CB, VGLUT1 or SYN expressing 
puncta in the perisomatic region of mPFC pyramidal neurons (A) and in neuropil (B) after Endo-N delivery in mPFC 
slices. (A) Perisomatic puncta density measured as the number of puncta/ μm of the pyramidal cell soma perimeter. (B) 
Neuropil density measured as the number of puncta/ μm
2
 of tissue. Asterisks in bars indicate statistically significant 
differences between groups (see graph legend) after one-way ANOVA followed by Bonferroni’s correction; p<0.05 (), 
p<0.01 (), p<0.001 (). 
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 113 Discussion 
1. PSA-NCAM EXPRESSION IN THE ADULT mPFC 
In the mPFC of adult rats, PSA-NCAM expression is widely distributed through 
every region and layer and can be found in neuronal somata and neuropil elements. 
As it has been commented in the introduction of this thesis, PSA-NCAM 
expressing neurons in the mPFC of adult rats correspond to different interneuronal 
subpopulations (attending to their expression of different calcium binding proteins 
and neuropeptides); the majority of them express CB, few of them express CR and 
almost none of them was found to co-express PV (Varea et al. 2005; Gómez-Climent 
et al. 2010). The number of PSA-NCAM expressing interneurons in this region is 
stable over lifetime (Varea et al. 2009), but pharmacological manipulations of 
monoaminergic neurotransmission (present work and Varea et al. 2007a) can 
decrease or increase it, indicating that inhibitory neurons in the mPFC can probably 
stop expressing, express “de novo” or re-express PSA-NCAM. Nevertheless, the 
percentages of PSA-NCAM expressing interneurons belonging to different 
interneuron subpopulations did not change, at least after D2R agonist treatment. 
Moreover, a very similar neurochemical phenotype has been found in PSA-NCAM 
expressing neurons in the mPFC of adult humans (Varea et al. 2007), mice (Nacher 
et al. 2010, Gómez-Climent et al. 2010) and cats (Varea et al. 2011), with only minor 
differences in the percentages across species. Together, all these data suggest that 
PSA-NCAM is always expressed by the same subgroups of mPFC interneurons, 
although additional studies exploring these interneurons in other species or after 
different pharmacological or behavioral conditions are necessary to confirm this 
hypothesis.  It is also possible that all, or a subset of PSA-NCAM expressing 
interneurons retain this expression constitutively since their generation during 
embryonic development (Gómez-Climent el al. 2010; Varea et al. 2005) and could 
probably switch on and off this expression depending on synaptic activity. 
The PSA-NCAM expressing puncta that surround pyramidal neurons in the 
mPFC of adult rats also seem to correspond to inhibitory and synaptic elements, as it 
has been described before for neocortical neuropil elements expressing this molecule 
(Gómez-Climent et al. 2010). Surprisingly, despite the fact that it is extremely rare to 
find this molecule in neuronal somata expressing PV (Varea et al., 2005; Gomez-
Climent et al., 2010), we have found that co-expression of PV and PSA-NCAM is 
common in perisomatic puncta on pyramidal neurons. This suggests that in PV 
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expressing interneurons, PSA-NCAM may have a restricted expression pattern, 
similar to that of mature hippocampal granule neurons, which only express PSA-
NCAM in their axons, but not in their somata or dendrites (Seki and Arai, 1999). 
Moreover, PSA-NCAM expression in this puncta may be regulated by the 
manipulation of dopamine neurotransmission in the mPFC, as demonstrated in the 
present work. 
Although both polysialyltransferases, ST8SiaII and ST8SiaIV, are present in 
the adult mPFC (see Oltmann-Norden et al. 2008 for review), the absence of PSA-
NCAM in the mPFC of ST8SiaIV-/- mice, but its normal expression in ST8SiaII-/- 
mice, indicate that ST8SiaIV is the solely responsible for PSA synthesis in 
prefrontocortical neurons during adulthood (Nacher et al. 2010). In fact, ST8SiaIV 
mRNA level in the mPFC increases after 4 days of D2R agonist treatment, while 
ST8SiaII gene expression does not change in any of the time points analyzed 
(present work). However, this does not necessarily imply that ST8SiaII could not be 
also responsible of PSA synthesis when it is induced by other pharmacological 
treatments or different behavioral challenges. 
Given its anti-adhesive properties, PSA-NCAM expression in neurons has 
been traditionally linked to plastic events, such as dendritic or spine remodeling and 
synaptogenesis (Sandi, 2004; Bonfanti, 2006; Gascon et al., 2007; Rutishauser, 
2008). However, a non-excluding insulating role for PSA-NCAM, preventing, totally or 
partially, the establishment of synapses should not be discarded. In fact, taking into 
account its steric effects (Johnson et al., 2005), the addition of PSA to NCAM in a 
synaptic contact should prevent or profoundly affect normal neurotransmission. 
Consequently, the expression of PSA-NCAM in certain neuropil elements and 
especially in perisomatic puncta on pyramidal cells may indicate that these structures 
are not establishing functional synaptic contacts. In connection with this idea, our 
laboratory has recently found that PSA-NCAM expressing interneurons have reduced 
synaptic input, reduced spine density and are less arborized than neighboring 
interneurons lacking PSA-NCAM, which suggests that they are partially disconnected 
from cortical circuitry (Gomez-Climent et al., 2010).  
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2. RELATIONSHIP BETWEEN PSA-NCAM EXPRESSING NEURONS AND 
DOPAMINERGIC INNERVATION IN THE mPFC 
Interneurons in the mPFC express D2R (Santana et al. 2009), especially those 
expressing PV, but also, to a lesser extent, those expressing CB (Le Moine and 
Gaspar, 1998). We have found that most PSA-NCAM expressing neurons in the 
mPFC co-express D2R and CB. Since it has been demonstrated in several species 
that PSA-NCAM expressing cells are mainly a subpopulation of calbindin expressing 
interneurons (Gómez-Climent et al. 2010, Nacher et al. 2010, Varea et al. 2005, 
2007c and unpublished results), it may be possible that they represent those 
displaying D2R expression. 
Interneurons in the mPFC are common targets of dopaminergic innervation 
coming from the VTA and some of these dopaminergic contacts have the morphology 
characteristic of symmetric synapses (Sesack et al., 1995, 1998). Interneurons 
expressing PV appear to be the main target of dopaminergic terminals (Sesack et al., 
1995, 1998) and although they do not express PSA-NCAM in their all extension, 
basket axon terminals in rats and PV cartridges in humans have been shown to 
express this molecule (present work and Arellano et al. 2002). Our study is the first to 
report dopaminergic fibers in close apposition to CB interneurons, suggesting that 
dopamine may also modulate their function. This hypothesis is also supported by our 
finding that D2R are present in this interneuronal subtype. Since we have found that 
some dopaminergic puncta appear to contact PSA-NCAM expressing interneurons 
and that some of them display synaptophysin expression, it is reasonable to think 
that, at least part of these structures, may be synaptic contacts. 
3. THE LESION OF THE DOPAMINE MESOCORTICAL PATHWAY 
DECREASES THE EXPRESSION OF PLASTICITY-RELATED PROTEINS 
6-OHDA-induced depletion of cortical dopaminergic terminals produces a 
significant reduction in PSA-NCAM expression in all prefrontocortical regions. This is 
consistent with other studies showing that modulation of dopaminergic 
neurotransmission by cocaine also affects PSA-NCAM expression in the 
hippocampus (Mackowiak et al., 2005) and that the expression of other cell adhesion 
molecules, such as L1 may also be regulated by 6-OHDA lesion (Poltorak et al., 
1997). Given the implication of PSA-NCAM in neuronal structural plasticity (Bruses 
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and Rutishauser, 2001, Sandi, 2004) and the modulation of its expression by 
dopamine, it is reasonable to think that the ability of neurons in this region to undergo 
neuritic and/or synaptic remodeling may be affected after specific dopamine 
depletion. In fact, a study using neonatal rats has described dendritic atrophy in 
pyramidal neurons of the mPFC (Sherren and Pappas, 2005). We still do not know 
whether neuritic or spine remodeling occur in adult mPFC neurons after lesioning the 
VTA, but our finding of a concomitant reduction in synaptophysin probably reflects a 
decrease in synaptic density (Eastwood and Harrison, 2001, Masliah et al., 1990), 
which may occur in parallel to neuronal structural remodeling. This regressive event 
may be triggered via PSA-NCAM downregulation, since the removal of PSA from 
NCAM blocks the formation of synapses (Dityatev et al., 2004). Supporting this fact, 
we have recently found that the downregulation of PSA-NCAM expression in the 
amygdala after chronic fluoxetine treatment is accompanied by a concomitant 
decrease in synaptophysin expression (Varea et al., 2007b). Conversely, this 
treatment induces upregulation of both PSA-NCAM and synaptophysin expression in 
the mPFC (Varea et al., 2007a, 2007b). 
PSA-NCAM expressing cells in the mPFC are mainly interneurons and puncta 
expressing this molecule in the neuropil, also appear to belong to these cells (Varea 
et al., 2005; Gómez-Climent el al. 2010, present work). Consequently, changes in 
PSA-NCAM expression should affect primarily inhibitory networks. This hypothesis is 
supported by our finding of a concomitant prefrontocortical downregulation of GAD67 
expression after VTA lesion. This is consistent with similar studies reporting a 
decrease in GAD67 mRNA expression in the prelimbic cortex of adult rats (Retaux et 
al.,1994). Interestingly, this downregulation was due to a change in GAD67 
expression in a subset of interneurons located in the prelimbic cortex deep layers, a 
region displaying a considerable density of PSA-NCAM expressing neurons (Varea et 
al., 2005). 
4. EFFECTS OF D2R AGONIST AND ANTAGONIST TREATMENTS ON mPFC 
NEURONAL CIRCUITRY 
Our results suggest that the effects of DA on PSA-NCAM, SYN and GAD67 
expression in the mPFC are mediated by D2R, since agonists for this receptor 
upregulate the expression of these molecules and the opposite effect is found after 
treatment with D2R specific antagonists. However, although the data are consistent 
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with a D2R-mediated effect, due to the dose and pharmacology of the drugs used, 
alternative explanations may also exist. 
In different telencephalic regions, including the mPFC, changes in PSA-NCAM 
expression correlate well with neuronal structural remodeling. While upregulation of 
PSA-NCAM expression is observed in parallel to dendritic outgrowth or increases in 
spine density, its downregulation accompanies dendritic atrophy or decreases in 
synaptic density (Cordero et al., 2005; Varea et al., 2007a). Our gene expression 
study during PPHT treatment indicates that the regulation of PSA-NCAM expression 
may be mediated by changes in the expression of the polysialyltransferases and 
NCAM, since st8siaIV mRNA levels in the mPFC increased after four days of 
treatment and ncam gene expression decreased at the end of the treatment.  
Previous data have indicated the involvement of D2R in neuronal remodeling 
and are consistent with the dynamics of PSA-NCAM expression that we observe after 
our pharmacological manipulations. There is previous evidence that dopamine acting 
through D2R is capable of inducing changes in cortical synapses similar to those 
described in our study. A significant decrease in synaptic density in the rat PFC has 
been observed after administration of a selective D2R antagonist. Conversely, 
treatment with the selective D2R agonist PPHT (the same compound used in our 
study) increases synaptic density in this region (Sugahara and Shiraishi, 1999). The 
effects of chronic haloperidol treatment on synaptic plasticity appear to be more 
complex and probably depend on the duration of the treatment. Sixteen weeks of 
haloperidol treatment lead to a reduction of axon terminals with asymmetric synapses 
in the rat mPFC (Benes et al., 1985). However, chronic treatment for 3 weeks 
increases synapses on dendritic shafts and dendritic spines (Klintzova et al., 1989) 
and a 16 week treatment increases synaptophysin mRNA expression (Eastwood et 
al., 1997). Other study has failed to report changes in synaptophysin expression in 
the mPFC after chronic haloperidol treatment (Nakahara et al., 1998).  
Our results indicate that the number of excitatory synapses is not affected in 
the mPFC neuropil after chronic PPHT treatment, because we do not detect changes 
in the expression of VGLUT1 in this cortical region. We have no data on the 
expression of markers of excitatory synapses in the mPFC after chronic D2R 
antagonist treatment. Previous ultrastructural analyses using chronic haloperidol 
treatment have rendered contradictory results. The study by Klintzova et al. (1989) 
indicated an increase in the number excitatory synapses because it found a higher 
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number of synapses on dendritic spines, which are mainly excitatory. By contrast, 
Benes et al. (1985), found a reduction in the number of asymmetric synapses in the 
mPFC.  
By contrast, pharmacological manipulation of D2R appears to have a profound 
effect on inhibitory neurotransmission in the mPFC. Dopamine enhances the activity 
of interneurons in the PFC and induces the release of GABA from these cells (Retaux 
et al., 1994). The opposite effects have been observed after acute administration of 
haloperidol (Bourdelais and Deutch, 1994). Our results with haloperidol and PPHT 
treatments give support to these studies, indicating a role for D2R in the modulation 
of GABAergic neurotransmission in the mPFC. Moreover, our gene expression study 
showed that the two enzymes responsible for GABA synthesis are affected by D2R 
manipulation, since four days of PPHT treatment increased mRNA levels of both 
gad65 and gad67 genes in the mPFC. The upregulation of GAD65/67 protein 
expression in the neuropil also induced by PPHT probably reflects an increase in 
inhibitory synapses on pyramidal neurons, since the number of puncta expressing 
these GABA-synthesizing enzymes also increases in the peridendritic and 
perisomatic regions of these cells.  
In the perisomatic region of pyramidal neurons we also detect a PPHT-
induced increase in the density of puncta expressing PV, a calcium binding protein 
expressed by many fast spiking/basket interneurons. A direct effect of PPHT in these 
inhibitory structures is likely, because D2R are particularly abundant in basket 
interneurons (Le Moine and Gaspar, 1998) and D2R agonists activate these cells 
(Tseng and O'Donnell, 2007). Moreover, activation of D2R attenuates excitatory 
synaptic transmission in the adult PFC, involving GABA release by local interneurons 
(Retaux et al., 1994).  
However, conflicting results regarding these effects of D2R activation on 
inhibitory neurotransmission have also been reported (Seamans et al., 2001; Gao et 
al., 2003; Trantham-Davidson et al., 2004). Moreover, although it is reasonable to 
think that most of the perisomatic immunoreactive puncta correspond to inhibitory 
axo-somatic synapses, the density of perisomatic SYN puncta is not affected by 
PPHT and there is a decrease in the percentage of PV expressing puncta expressing 
SYN, which may indicate that some of the new perisomatic puncta expressing 
GAD65/67 and PV induced by PPHT are not functional synapses. In fact, our gene 
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expression study during PPHT treatment also failed into find significant differences in 
the level of syn gene expression in any of the time points analyzed. 
These effects of PPHT on inhibitory structures occur in parallel to a decrease 
in pyramidal neuron spine density. This is, to our knowledge, the first report 
describing effects of a selective D2R agonist on this structural parameter. However, 
there are previous evidences suggesting that manipulation of dopamine levels 
modulates spine density in this cortical region. Chronic treatments with drugs that 
promote dopaminergic neurotransmission (among other effects), such as cocaine, 
phencyclidine and amphetamine, have rendered conflicting results: Although there is 
evidence, at least in primates, that long term amphetamine treatment decreases 
spine density in the mPFC (Selemon et al., 2007), there are also reports describing 
increases in spine density (Robinson and Kolb, 1999; Robinson et al., 2001) and in 
the density of axospinous synapses (Morshedi et al., 2009). In consonance with our 
results, it is also important to note that either acute stress or exposure to estrogens, 
which decrease spine density in rat mPFC pyramidal neurons (Radley et al., 2005; 
Hao et al., 2006), also increase dopamine accumulation (Mangiavacchi et al., 2001; 
Arnsten et al., 2010). However, dopamine depletion from the mPFC, genetic 
deletions of D2R or decreases in dopamine levels frequently observed in 
schizophrenia or after chronic stress are also associated with reductions in spine 
density in this area (Wang and Deutch, 2008; Wang et al., 2009). Additionally, 
cultures of frontocortical neurons of fetal rats in the presence of a D2R selective 
agonist resulted in a dramatic increase in neurite length and branching, and these 
effects were blocked by D2R antagonists (Todd, 1992). Similar structural effects were 
found when a neuronal cell line transfected with D2R was treated with a specific D2R 
agonist (Swarzenski et al., 1994). Chronic treatment with the specific antagonist 
haloperidol reduce spine density in the striatum (Kelley et al., 1997) and this 
antagonist also induces a downregulation of spinophilin expression, a protein 
selectively located in dendritic spines and an increased phosphorylation of MAP2 in 
the mPFC, which may be indicative of dendritic atrophy (Lidow et al., 2001). These 
conflicting results may indicate that dopamine has an inverted-U shaped influence on 
mPFC pyramidal neuron structure, similar to its influence on the function of this 
cortical region (Arnsten, 2009).  
The effects of PPHT on spine density may be directly mediated by D2R 
present in pyramidal neurons (these receptors can be localized in their spines) (Yao 
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et al., 2008); but also indirectly, through D2R present in interneurons (Santana et al., 
2009). In fact, previous reports showed that D2R agonists decrease AMPA receptor 
expression in mPFC pyramidal neurons (Sun et al., 2005), which in turn decreases 
spine density in these cells (Nimchinsky et al., 2002). 
5. EFFECTS OF PSA DEPLETION FROM THE mPFC 
 Although the effects of PSA depletion in the mPFC neuropil are only restricted 
to VGLUT1 expression, those on the perisomatic region of pyramidal neurons are 
more dramatic, increasing the density of perisomatic puncta expressing GAD65/67, 
PV and SYN, as well as the percentage of PV puncta that co-express SYN. 
Moreover, similar results were found in mPFC organotypic cultures after two days of 
PSA depletion. A possible explanation for these effects is that the removal of PSA 
from NCAM may activate some perisomatic synapses, which were previously blocked 
by the presence of PSA. Consequently, the expression of molecules related to active 
inhibitory neurotransmission, such as SYN, GAD65/67 and PV, is increased and 
more puncta become detectable. These results are in agreement with a previous 
study on the developing visual cortex, in which PSA depletion induced precocious 
maturation of perisomatic innervation by basket interneurons, resulting in enhanced 
inhibitory synaptic transmission (Di Cristo et al., 2007). Thus, the presence of PSA-
NCAM in control adult mPFC may act as a regulator of perisomatic inhibitory 
innervation.  
PSA removal from the mPFC also induces dramatic effects on dendritic spine 
density in pyramidal neurons. Since these excitatory cells do not express PSA-NCAM 
during adulthood (Gomez-Climent et al., 2010), this loss of spines, as well as the 
decrease in VGLUT1 expression in the neuropil, must be a secondary effect 
mediated by interneurons. However, in mPFC organotypic cultures VGLUT1 
expression increases in the mPFC neuropil and also in the perisomatic region of 
pyramidal neurons after two days of PSA depletion. This may indicate that the 
decrease in excitatory neurotransmission detected in the mPFC after long-term PSA 
depletion is a rebound effect mediated by interneurons in response to an initial 
cortical hiperexcitability. 
Removal of PSA from the mPFC completely blocks the effects of PPHT 
treatment on SYN and GAD65/67 expression in the neuropil and in the number of 
peridendritic GAD65/67 puncta on pyramidal neurons. Consequently, the appearance 
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of new structures belonging to interneurons and new synapses (presumably inhibitory 
ones, since VGLUT1 expression is not affected) may need the expression of PSA-
NCAM. The anti-adhesive properties of this molecule may favor the 
extension/formation of neurites and synapses from certain interneurons in a similar 
way to what have been described in hippocampal granule neurons (Saegusa et al., 
2004). The effects of Endo-N on PPHT-induced changes on perisomatic structures of 
pyramidal cells are more complex to interpret, since PSA depletion “per se” has 
important effects on these structures. Although it is known that PSA-NCAM is crucial 
for the maturation of these perisomatic inhibitory networks (Di Cristo et al., 2007), 
further research is needed to unravel the role of this molecule in the plasticity of 
these structures. 
Our results also show that PSA depletion has an effect on the dendritic 
structure of mPFC interneurons. Two days of PSA depletion in organotypic cultures 
decreased spine density in the dendrites of mPFC interneurons. A recent study from 
our laboratory has shown that in the hippocampus of control adult mice interneurons 
expressing PSA-NCAM have less dendritic spines than those lacking PSA-NCAM 
expression (Gómez-Climent et al. 2010). Unfortunately, in our present experiment we 
have not monitored individual interneurons for PSA-NCAM expression before PSA 
depletion and, consequently, our data derive from the general population of 
interneurons, comprised by those expressing and those lacking PSA-NCAM.  Future 
experiments following the structure of identified PSA-NCAM expressing interneurons 
should be performed to identify what subpopulation of interneurons is affected by 
PSA depletion and whether the removal of PSA affects initially the structure of those 
previously expressing this molecule. 
 The changes induced by PSA depletion or by alterations in the degree of 
NCAM polysialylation, may not only be caused by the regulation of NCAM adhesive 
properties, but also by the influence of PSA on NCAM-mediated signaling (see 
(Gascon et al., 2007) for review). Moreover, interference on NCAM may also impair 
dopaminergic neurotransmission, since NCAM regulates the trafficking, 
internalization and degradation of D2R (Xiao et al., 2009). 
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6. NEUROLOGICAL AND PSYCHIATRIC DISEASES 
The results of our experiments using 6-OHDA lesion of the VTA and the 
consequent depletion of dopamine from the mPFC may have implications in our 
understanding of Parkinson’s disease. This neurological disorder is mainly 
characterized by the disappearance of dopaminergic neurons in the substantia nigra, 
which are responsible of the motor problems associated with this disorder. However, 
it is known that neurons synthesizing dopamine in the VTA are also affected and, 
consequently, the dopaminergic mesocortical pathway. Different lines of evidence 
point to the lesion of this pathway as the responsible of certain cognitive deficits 
associated to Parkinson’s disease. Moreover, this lesion may also be responsible of 
the prevalence in parkinsonian patients of psychiatric disorders in which the medial 
prefrontal cortex has a critical role. However, the exact contribution of dopaminergic 
deficiency to cognitive defects in Parkinson's disease is not well understood. Our 
results suggest that a reduction of dopaminergic innervation in the mPFC induces 
synaptic plasticity that may lead to altered wiring of intrinsic GABAergic circuits. In 
fact, humans with Parkinson's disease show reduced cortical synaptophysin 
expression, which is even more decreased in demented patients (Zhan et al.,1993), 
and decreased GAD expression in the prefrontal cortex (Lanoue et al., 2010). Our 
results suggest that PSA-NCAM is involved in these changes. This molecule is also 
expressed in the human PFC (Varea et al., 2007c), and, consequently, studies of 
PSA-NCAM expression in the prefrontal cortex of Parkinson's disease patients may 
be extremely interesting. 
Dopamine and its receptors, especially D2R, are profoundly implicated in the 
etiology and the treatment of psychiatric disorders such as major depression or 
schizophrenia. Our results linking dopaminergic neurotransmission, structural 
plasticity and inhibitory neurons may have implications in the understanding of the 
molecular bases of these disorders, since decreased levels of dopamine (Di Forti et 
al., 2007; Arnsten, 2009) and D2R (Knable et al., 2001; Zhang et al., 2010), as well 
as deficits in GABAergic neurotransmission and PV expressing interneurons have 
been found in the PFC of patients and animal models of major depression and 
schizophrenia (Volk and Lewis, 2002; Schiavone et al., 2009).  
The administration of dopamine receptor antagonists or drugs that reduce 
dopamine levels, induce symptoms resembling those of endogenous depression 
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(Willner, 1983). Conversely, dopamine receptor agonists, as well as drugs that 
increase dopamine function, have antidepressant-like profiles in animal models of 
depression (Muscat et al., 1992) and have been reported to have efficacy in the 
treatment of human depression (Willner et al., 2005). Dopamine can act by binding to 
different receptors, but the D2 subtype seems to play a key role in the response to 
antidepressant treatments (Gershon et al., 2007). The present results show that 
changes in neuronal remodeling and synaptic plasticity, as indicated by the 
modulation of the expression of PSA-NCAM, synaptophysin and molecules related to 
inhibitory neurotransmission, may participate in the antidepressant effects of 
dopamine mediated by D2R. We have recently shown that similar neuronal plasticity 
mediates the effects of antidepressants acting on serotoninergic neurotransmission 
(Varea et al., 2007a, 2007b), providing a substrate to the neuroplastic hypothesis of 
depression (Castren, 2005; Duman, 2002).  
Our results may also have important implications in the understanding of the 
molecular bases of schizophrenia and antipsychotic treatment, since dopamine 
dysregulation underlies positive psychotic symptoms in schizophrenic patients (Di 
Forti et al., 2007) and D2R antagonists are the most widely used antipsychotics. 
Moreover, neuroimaging studies have revealed structural changes in the mPFC of 
patients suffering from schizophrenia (Harrison, 1999). PSA-NCAM expression may 
be involved in these modifications, since it is present in the PFC of adult humans 
(Varea et al., 2007c) and alterations in the number of PSA-NCAM expressing 
neurons have been described in the hippocampus of schizophrenic patients 
(Barbeau et al., 1995), a region which, like the mPFC, also shows structural 
modifications in these patients (McCarley et al., 1999). It would be thus interesting to 
perform PSA-NCAM expression analysis in the mPFC of postmortem tissue from 
depressed and schizophrenic patients, because, although traditionally the etiology of 
these psychiatric disorders has been attributed to neurochemical imbalances in the 
mPFC and other cerebral regions, recent hypotheses suggest that alterations in the 
structural plasticity of neuronal networks may also be involved in these mental 
diseases (Castren 2005; Duman et al., 1999; Frost et al., 2004). The fact that PSA-
NCAM expression is restricted to interneurons in the mPFC is also very interesting 
(Varea et al., 2005, 2007c), because there are evidences indicating abnormalities in 
the density and distribution of these inhibitory cells in patients suffering schizophrenia 
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and major depression (Benes and Berretta, 2001; Daskalakis et al., 2007; Rajkowska 
et al., 2007). 
Interestingly, there is evidence for a relationship between dysregulation of 
NCAM and its posttranslational modifications and the neural abnormalities found in 
different mood disorders (Vawter, 2000). Moreover, ST8SiaII, one of the enzymes 
responsible for NCAM polysialylation is a candidate susceptibility gene for 
schizophrenia and bipolar disorder (Arai et al., 2004; Tao et al., 2007) and PSA-
NCAM expression is altered in the brain of schizophrenics (Barbeau et al., 1995). Our 
results showing the involvement of PSA-NCAM in the plasticity induced by D2R 
manipulation and its necessary presence for the maintenance of mPFC perisomatic 
inhibition also support the idea that altered PSA-NCAM expression may participate in 
the pathogenesis of these psychiatric disorders. 
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1. PSA-NCAM expressing cells are widely distributed throughout every region 
and layer in the mPFC of adult rats and show a unipolar, bipolar or multipolar 
morphology. 
 
2. There is a clear lamination pattern of PSA-NCAM expression in the mPFC 
neuropil, with low expression in superficial layers, moderate expression in 
layer III and intense expression in deep layers. 
 
3. Pyramidal neurons in the mPFC do not express PSA-NCAM, but their somata 
are surrounded by PSA-NCAM expressing puncta, which co-express markers 
of inhibitory or synaptic structures. A high percentage of these PSA-NCAM 
expressing puncta co-express the calcium binding protein PV. 
 
4. Most PSA-NCAM expressing somata in the mPFC co-express D2R and the 
majority of them pertain to the CB expressing interneuron subpopulation. 
 
5. Dopaminergic fibers in the mPFC are closely apposed to PSA-NCAM 
expressing interneurons and some of them display SYN expression. 
 
6. Both the lesion of the mesocortical dopamine pathway and the chronic 
treatment with a D2R antagonist, decrease the expression of PSA-NCAM, 
GAD67 and SYN in the mPFC neuropil. Chronic treatment with a D2R agonist 
has the opposite effects. 
7. During chronic treatment with a D2R agonist, the mPFC show temporal 
differences in the expression of the majority of the plasticity related genes 
analyzed (St8siaIV, ncam, gad65 and gad67), while others do not change their 
expression in any of the time points analyzed (syn and St8siaII). 
8. D2R agonist treatment increases the number of PSA-NCAM expressing 
interneurons and that of elements expressing this molecule in the neuropil and 
the perisomatic region of pyramidal neurons. This treatment also increases the 
expression of SYN in the neuropil and that of inhibitory markers in the neuropil 
and the perisomatic and peridendritic regions of pyramidal neurons. By 
contrast, spine density is reduced in these neurons. 
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9. PSA depletion from the mPFC using the enzyme Endo-N, prevents the effects 
of D2R agonist treatment on the neuropil and the peridendritic region of 
pyramidal neurons. However, changes in the perisomatic region or the spines 
of these principal neurons are not affected. 
10.  PSA depletion by itself increases the expression of SYN and inhibitory 
markers in the perisomatic region and reduces spine density in pyramidal 
neurons. 
11.  Short term PSA depletion in vitro decreases spine density in mPFC 
interneurons and increases the number of puncta expressing inhibitory, 
excitatory and synaptic markers surrounding the somata of pyramidal neurons. 
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